BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Venook AP, Papandreou C, Furuse J, Ladrón de Guevara L. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. The Oncologist 2010;15:5-13. [DOI: 10.1634/theoncologist.2010-s4-05] [Cited by in Crossref: 575] [Cited by in F6Publishing: 345] [Article Influence: 52.3] [Reference Citation Analysis]
Number Citing Articles
1 Han JJ, Chen Y, Nan YC, Yang YL. Extremely high titer of hepatitis B surface antigen antibodies in a primary hepatocellular carcinoma patient: A case report. World J Clin Cases 2021; 9(28): 8492-8497 [DOI: 10.12998/wjcc.v9.i28.8492] [Reference Citation Analysis]
2 Lu S, Gao Y, Huang X, Wang X. Cantharidin exerts anti-hepatocellular carcinoma by miR-214 modulating macrophage polarization. Int J Biol Sci. 2014;10:415-425. [PMID: 24719559 DOI: 10.7150/ijbs.8002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
3 Reichl P, Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). Oncol Rep. 2016;36:613-625. [PMID: 27278244 DOI: 10.3892/or.2016.4842] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
4 Murakami Y, Tanahashi T, Okada R, Toyoda H, Kumada T, Enomoto M, Tamori A, Kawada N, Taguchi YH, Azuma T. Comparison of hepatocellular carcinoma miRNA expression profiling as evaluated by next generation sequencing and microarray. PLoS One. 2014;9:e106314. [PMID: 25215888 DOI: 10.1371/journal.pone.0106314] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
5 Yang H, Chen K, Wei Y, Liu F, Li H, Zhou Z, Li B. Treatment of spontaneous ruptured hepatocellular carcinoma: A single-center study. Pak J Med Sci 2014;30:472-6. [PMID: 24948961 DOI: 10.12669/pjms.303.4001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.1] [Reference Citation Analysis]
6 Rojpibulstit P, Kittisenachai S, Puthong S, Manochantr S, Gamnarai P, Jitrapakdee S, Roytrakul S. Hep88 mAb-initiated paraptosis-like PCD pathway in hepatocellular carcinoma cell line through the binding of mortalin (HSPA9) and alpha-enolase. Cancer Cell Int 2014;14:69. [PMID: 25788858 DOI: 10.1186/s12935-014-0069-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
7 Caglevic C, Silva S, Mahave M, Torres J, Rolfo C, Gallardo J, Carrasco P. Hepatocellular carcinoma in identical twins in Chile: case report. Ecancermedicalscience 2016;10:708. [PMID: 28105079 DOI: 10.3332/ecancer.2016.708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
8 张超, 李刚. 甲胎蛋白在乙型肝炎病毒诱导肝癌发生中的作用及临床应用展望. 世界华人消化杂志 2015; 23(20): 3171-3181 [DOI: 10.11569/wcjd.v23.i20.3171] [Reference Citation Analysis]
9 Hu X, Wang R, Ren Z, Liu X, Gu J, Cui G, Li Q. MiR-26b suppresses hepatocellular carcinoma development by negatively regulating ZNRD1 and Wnt/β-catenin signaling. Cancer Med 2019;8:7359-71. [PMID: 31637871 DOI: 10.1002/cam4.2613] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
10 Hu ZD, Jiang Y, Sun HM, Wang JW, Zhai LL, Yin ZQ, Yan J. KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers. Biomed Res Int 2021;2021:2676745. [PMID: 33490265 DOI: 10.1155/2021/2676745] [Reference Citation Analysis]
11 Gani SA, Muhammad SA, Kura AU, Barahuie F, Hussein MZ, Fakurazi S. Effect of protocatechuic acid-layered double hydroxide nanoparticles on diethylnitrosamine/phenobarbital-induced hepatocellular carcinoma in mice. PLoS One 2019;14:e0217009. [PMID: 31141523 DOI: 10.1371/journal.pone.0217009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL, Lee FT Jr. Liver Ablation: Best Practice. Radiol Clin North Am 2015;53:933-71. [PMID: 26321447 DOI: 10.1016/j.rcl.2015.05.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
13 Allain J, Opare-sem O. Screening and diagnosis of HBV in low-income and middle-income countries. Nat Rev Gastroenterol Hepatol 2016;13:643-53. [DOI: 10.1038/nrgastro.2016.138] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
14 郭慧敏, 李建生, 张金平, 李东颖, 李会芬. 血清sCD25测定在肝细胞癌诊断中的意义. 世界华人消化杂志 2014; 22(34): 5344-5349 [DOI: 10.11569/wcjd.v22.i34.5344] [Reference Citation Analysis]
15 Guo T, Wu P, Liu P, Chen B, Jiang X, Gu Y, Liu Z, Li Z. Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis. J Cancer 2018;9:2640-9. [PMID: 30087704 DOI: 10.7150/jca.25056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
16 Yang CK, Wang XK, Liao XW, Han CY, Yu TD, Qin W, Zhu GZ, Su H, Yu L, Liu XG, Lu SC, Chen ZW, Liu Z, Huang KT, Liu ZT, Liang Y, Huang JL, Xiao KY, Peng MH, Winkle CA, O'Brien SJ, Peng T. Aldehyde dehydrogenase 1 (ALDH1) isoform expression and potential clinical implications in hepatocellular carcinoma. PLoS One 2017;12:e0182208. [PMID: 28792511 DOI: 10.1371/journal.pone.0182208] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
17 Loosen SH, Schueller F, Trautwein C, Roy S, Roderburg C. Role of circulating microRNAs in liver diseases. World J Hepatol 2017; 9(12): 586-594 [PMID: 28515844 DOI: 10.4254/wjh.v9.i12.586] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
18 Yang S, Luo C, Gu Q, Xu Q, Wang G, Sun H, Qian Z, Tan Y, Qin Y, Shen Y. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. Oncotarget. 2016;7:5461-5469. [PMID: 26701727 DOI: 10.18632/oncotarget.6684] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
19 Shi J, Song S, Li S, Zhang K, Lan Y, Li Y. TNF-α/NF-κB signaling epigenetically represses PSD4 transcription to promote alcohol-related hepatocellular carcinoma progression. Cancer Med 2021;10:3346-57. [PMID: 33932127 DOI: 10.1002/cam4.3832] [Reference Citation Analysis]
20 He C, Zhang X, Li C, Peng W, Wen TF, Yan LN, Yang J, Lu W. Changes of alpha-fetoprotein levels could predict recurrent hepatocellular carcinoma survival after trans-arterial chemoembolization. Oncotarget 2017;8:85599-611. [PMID: 29156744 DOI: 10.18632/oncotarget.20343] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
21 Sheppard S, Guedes J, Mroz A, Zavitsanou AM, Kudo H, Rothery SM, Angelopoulos P, Goldin R, Guerra N. The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma. Nat Commun 2017;8:13930. [PMID: 28128200 DOI: 10.1038/ncomms13930] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
22 Li G, Shen Q, Li C, Li D, Chen J, He M. Identification of circulating MicroRNAs as novel potential biomarkers for hepatocellular carcinoma detection: a systematic review and meta-analysis. Clin Transl Oncol 2015;17:684-93. [PMID: 25956842 DOI: 10.1007/s12094-015-1294-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
23 Su SC, Ho YC, Liu YF, Reiter RJ, Chou CH, Yeh CM, Lee HL, Chung WH, Hsieh MJ, Yang SF. Association of melatonin membrane receptor 1A/1B gene polymorphisms with the occurrence and metastasis of hepatocellular carcinoma. Oncotarget 2017;8:85655-69. [PMID: 29156748 DOI: 10.18632/oncotarget.21107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Wood LD, Heaphy CM, Daniel HD, Naini BV, Lassman CR, Arroyo MR, Kamel IR, Cosgrove DP, Boitnott JK, Meeker AK, Torbenson MS. Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Mod Pathol. 2013;26:1586-1593. [PMID: 23640129 DOI: 10.1038/modpathol.2013.68] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
25 Cheng CW, Su JL, Lin CW, Su CW, Shih CH, Yang SF, Chien MH. Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features. PLoS One 2013;8:e56130. [PMID: 23457512 DOI: 10.1371/journal.pone.0056130] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
26 Wu L, Hu A, Tam N, Zhang J, Lin M, Guo Z, He X. Salvage liver transplantation for patients with recurrent hepatocellular carcinoma after curative resection. PLoS One 2012;7:e41820. [PMID: 22848619 DOI: 10.1371/journal.pone.0041820] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
27 Scott CS, Jinot J. Trichloroethylene and cancer: systematic and quantitative review of epidemiologic evidence for identifying hazards. Int J Environ Res Public Health 2011;8:4238-72. [PMID: 22163205 DOI: 10.3390/ijerph8114238] [Cited by in Crossref: 66] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
28 Savić R, He X, Fiel I, Schuchman EH. Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer. PLoS One 2013;8:e65620. [PMID: 23724146 DOI: 10.1371/journal.pone.0065620] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
29 Ni JY, Xu LF, Sun HL, Zhou JX, Chen YT, Luo JH. Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients. J Cancer Res Clin Oncol. 2013;139:2021-2033. [PMID: 24072235 DOI: 10.1007/s00432-013-1530-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
30 Vongsuvanh R, van der Poorten D, George J. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific. Hepatol Int 2013;7 Suppl 2:823-32. [PMID: 26202297 DOI: 10.1007/s12072-013-9453-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
31 La Torre G, Mannocci A, Saulle R, Colamesta V, Meggiolaro A, Mipatrini D, Sinopoli A. Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013). Hum Vaccin Immunother 2016;12:2299-311. [PMID: 27105443 DOI: 10.1080/21645515.2016.1166328] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
32 Yang Z, Duan J, Wang J, Liu Q, Shang R, Yang X, Lu P, Xia C, Wang L, Dou K. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy. Int J Nanomedicine 2018;13:1851-65. [PMID: 29618926 DOI: 10.2147/IJN.S155537] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 8.3] [Reference Citation Analysis]
33 Chung JW, Kim BH, Lee CS, Kim GH, Sohn HR, Min BY, Song JC, Park HK, Jang ES, Yoon H, Kim J, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Lee J, Ahn S, Kim JW. Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. PLoS One 2016;11:e0168189. [PMID: 27997559 DOI: 10.1371/journal.pone.0168189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
34 Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 172] [Article Influence: 24.1] [Reference Citation Analysis]
35 Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, Chulanov V. Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure. Genes (Basel) 2018;9:E483. [PMID: 30301171 DOI: 10.3390/genes9100483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Huang Y, Zhang C, Xiong J, Ren H. Emerging important roles of circRNAs in human cancer and other diseases. Genes Dis 2021;8:412-23. [PMID: 34179306 DOI: 10.1016/j.gendis.2020.07.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Li CW, Chang PY, Chen BS. Investigating the mechanism of hepatocellular carcinoma progression by constructing genetic and epigenetic networks using NGS data identification and big database mining method. Oncotarget 2016;7:79453-73. [PMID: 27821810 DOI: 10.18632/oncotarget.13100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
38 Khalid M, Brisson L, Tariq M, Hao Y, Guibon R, Fromont G, Mortadza SAS, Mousawi F, Manzoor S, Roger S, Jiang LH. Carcinoma-specific expression of P2Y11 receptor and its contribution in ATP-induced purinergic signalling and cell migration in human hepatocellular carcinoma cells. Oncotarget 2017;8:37278-90. [PMID: 28418839 DOI: 10.18632/oncotarget.16191] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
39 Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2014;342:223-230. [PMID: 22306342 DOI: 10.1016/j.canlet.2012.01.038] [Cited by in Crossref: 109] [Cited by in F6Publishing: 114] [Article Influence: 12.1] [Reference Citation Analysis]
40 Wang C, Zhu G, Yu M, Mi X, Qu H. miR-455 Inhibits the Viability and Invasion by Targeting RAB18 in Hepatocellular Carcinoma. J Oncol 2021;2021:9923454. [PMID: 34135963 DOI: 10.1155/2021/9923454] [Reference Citation Analysis]
41 Guo T, Liu P, Yang J, Wu P, Chen B, Liu Z, Li Z. Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. J Cancer 2019;10:4671-8. [PMID: 31528232 DOI: 10.7150/jca.32828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Ibrahim AS, Zaghloul H, Badria FA. Case report evidence of relationships between hepatocellular carcinoma and ochratoxicosis. PLoS One 2013;8:e71423. [PMID: 23977041 DOI: 10.1371/journal.pone.0071423] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
43 Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123-135. [PMID: 23344543 DOI: 10.1038/nrc3449] [Cited by in Crossref: 505] [Cited by in F6Publishing: 481] [Article Influence: 63.1] [Reference Citation Analysis]
44 Chen X, Yan CC, Zhang X, You ZH. Long non-coding RNAs and complex diseases: from experimental results to computational models. Brief Bioinform 2017;18:558-76. [PMID: 27345524 DOI: 10.1093/bib/bbw060] [Cited by in Crossref: 138] [Cited by in F6Publishing: 215] [Article Influence: 34.5] [Reference Citation Analysis]
45 Wu S, Ai H, Zhang K, Yun H, Xie F. Long Non-Coding RNA EGOT Promotes the Malignant Phenotypes of Hepatocellular Carcinoma Cells and Increases the Expression of HMGA2 via Down-Regulating miR-33a-5p. Onco Targets Ther 2019;12:11623-35. [PMID: 32021242 DOI: 10.2147/OTT.S218308] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
46 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yan Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver 2020;14:232-47. [PMID: 31158948 DOI: 10.5009/gnl18546] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
47 Hayashi A, Shibahara J, Misumi K, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Fukayama M. Histologic Assessment of Intratumoral Lymphoplasmacytic Infiltration Is Useful in Predicting Prognosis of Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0155744. [PMID: 27195977 DOI: 10.1371/journal.pone.0155744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
48 Jia J, Li H, Wang H, Chen S, Wang M, Feng H, Gao Y, Wang Y, Fang M, Gao C. Hepatitis B virus core antigen mutations predict post-operative prognosis of patients with primary hepatocellular carcinoma. J Gen Virol. 2017;98:1399-1409. [PMID: 28640739 DOI: 10.1099/jgv.0.000790] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
49 Khan AA, Alanazi AM, Jabeen M, Chauhan A, Ansari MA. Therapeutic potential of functionalized siRNA nanoparticles on regression of liver cancer in experimental mice. Sci Rep 2019;9:15825. [PMID: 31676815 DOI: 10.1038/s41598-019-52142-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
50 Teng CF, Li TC, Huang HY, Lin JH, Chen WS, Shyu WC, Wu HC, Peng CY, Su IJ, Jeng LB. Next-Generation Sequencing-Based Quantitative Detection of Hepatitis B Virus Pre-S Mutants in Plasma Predicts Hepatocellular Carcinoma Recurrence. Viruses 2020;12:E796. [PMID: 32722114 DOI: 10.3390/v12080796] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
51 Campbell PT, Newton CC, Freedman ND, Koshiol J, Alavanja MC, Beane Freeman LE, Buring JE, Chan AT, Chong DQ, Datta M, Gaudet MM, Gaziano JM, Giovannucci EL, Graubard BI, Hollenbeck AR, King L, Lee IM, Linet MS, Palmer JR, Petrick JL, Poynter JN, Purdue MP, Robien K, Rosenberg L, Sahasrabuddhe VV, Schairer C, Sesso HD, Sigurdson AJ, Stevens VL, Wactawski-Wende J, Zeleniuch-Jacquotte A, Renehan AG, McGlynn KA. Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults. Cancer Res. 2016;76:6076-6083. [PMID: 27742674 DOI: 10.1158/0008-5472.can-16-0787] [Cited by in Crossref: 72] [Cited by in F6Publishing: 47] [Article Influence: 18.0] [Reference Citation Analysis]
52 Farra R, Musiani F, Perrone F, Čemažar M, Kamenšek U, Tonon F, Abrami M, Ručigaj A, Grassi M, Pozzato G, Bonazza D, Zanconati F, Forte G, El Boustani M, Scarabel L, Garziera M, Russo Spena C, De Stefano L, Salis B, Toffoli G, Rizzolio F, Grassi G, Dapas B. Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness. Molecules 2018;23:E777. [PMID: 29597300 DOI: 10.3390/molecules23040777] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
53 Jeng KS, Sheen IS, Jeng WJ, Yu MC, Hsiau HI, Chang FY, Tsai HH. Activation of the sonic hedgehog signaling pathway occurs in the CD133 positive cells of mouse liver cancer Hepa 1-6 cells. Onco Targets Ther. 2013;6:1047-1055. [PMID: 23950652 DOI: 10.2147/ott.s44828] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
54 Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, Shiina S, Fontana A, Torzilli G. Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer. 2016;6:34-43. [PMID: 27995086 DOI: 10.1159/000449346] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
55 Lu L, Zeng J, Wen Z, Tang C, Xu N. Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults. Cochrane Database Syst Rev. 2019;2:CD012244. [PMID: 30776082 DOI: 10.1002/14651858.cd012244.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
56 Palanisamy S, Sabnis SC, Patel ND, Nalankilli VP, Vijai A, Palanivelu P, Ramkrishnan P, Chinnusamy P. Laparoscopic Major Hepatectomy-Technique and Outcomes. J Gastrointest Surg 2015;19:2215-22. [PMID: 26361772 DOI: 10.1007/s11605-015-2933-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
57 Fitian AI, Cabrera R. Disease monitoring of hepatocellular carcinoma through metabolomics. World J Hepatol 2017; 9(1): 1-17 [PMID: 28105254 DOI: 10.4254/wjh.v9.i1.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
58 Pedica F, Ruzzenente A, Bagante F, Capelli P, Cataldo I, Pedron S, Iacono C, Chilosi M, Scarpa A, Brunelli M. A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse. PLoS One. 2013;8:e68203. [PMID: 23874541 DOI: 10.1371/journal.pone.0068203] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
59 Wu ER, Chou YE, Liu YF, Hsueh KC, Lee HL, Yang SF, Su SC. Association of lncRNA H19 Gene Polymorphisms with the Occurrence of Hepatocellular Carcinoma. Genes (Basel) 2019;10:E506. [PMID: 31277475 DOI: 10.3390/genes10070506] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
60 Zhang YW, Chen Q, Li B, Li HY, Zhao XK, Xiao YY, Liu S, Zuo S. NAP1L1 Functions as a Tumor Promoter via Recruiting Hepatoma-Derived Growth Factor/c-Jun Signal in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:659680. [PMID: 34368121 DOI: 10.3389/fcell.2021.659680] [Reference Citation Analysis]
61 Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, Li J. The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity. Mol Ther 2021;29:1794-807. [PMID: 33484968 DOI: 10.1016/j.ymthe.2021.01.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
62 Bridges JF, Gallego G, Kudo M, Okita K, Han KH, Ye SL, Blauvelt BM. Identifying and prioritizing strategies for comprehensive liver cancer control in Asia. BMC Health Serv Res 2011;11:298. [PMID: 22047535 DOI: 10.1186/1472-6963-11-298] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
63 Jung HR, Kang HM, Ryu JW, Kim DS, Noh KH, Kim ES, Lee HJ, Chung KS, Cho HS, Kim NS, Im DS, Lim JH, Jung CR. Cell Spheroids with Enhanced Aggressiveness to Mimic Human Liver Cancer In Vitro and In Vivo. Sci Rep. 2017;7:10499. [PMID: 28874716 DOI: 10.1038/s41598-017-10828-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
64 Tao R, Li X, Ran R, Xiao Z, Zhang H, Kong H, Song Q, Huang Y, Wang L, Huang J. A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. Oncotarget 2017;8:5460-73. [PMID: 27705924 DOI: 10.18632/oncotarget.12348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Han H, Hu J, Lau MY, Feng M, Petrovic LM, Ji C. Altered methylation and expression of ER-associated degradation factors in long-term alcohol and constitutive ER stress-induced murine hepatic tumors. Front Genet 2013;4:224. [PMID: 24198826 DOI: 10.3389/fgene.2013.00224] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
66 Bao H, Su H. Long Noncoding RNAs Act as Novel Biomarkers for Hepatocellular Carcinoma: Progress and Prospects. Biomed Res Int 2017;2017:6049480. [PMID: 28835896 DOI: 10.1155/2017/6049480] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
67 Abdel-Rahman O, Elsayed Z. External beam radiotherapy for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2017;3:CD011314. [PMID: 28267205 DOI: 10.1002/14651858.CD011314.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
68 Mroweh M, Decaens T, Marche PN, Macek Jilkova Z, Clément F. Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5250. [PMID: 32722054 DOI: 10.3390/ijms21155250] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
69 Li CX, Yang XX, Wang HW, Li XC, Ng KT, Lo CM, Man K. FTY720 Suppresses Liver Tumor Growth and Metastasis by Reducing Circulating Regulating T Cells and Enhancing the Anti-Tumor Effect of Rapamycin. Onco Targets Ther 2020;13:4743-54. [PMID: 32547103 DOI: 10.2147/OTT.S234394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Jia X, Gao Y, Zhai D, Liu J, Wang Y, Jing LI, DU Z. Survivin is not a promising serological maker for the diagnosis of hepatocellular carcinoma. Oncol Lett. 2015;9:2347-2352. [PMID: 26137069 DOI: 10.3892/ol.2015.3050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
71 Li Z, Zhou Q, Zhou J, Duan X, Zhu J, Wang TD. In vivo fluorescence imaging of hepatocellular carcinoma xenograft using near-infrared labeled epidermal growth factor receptor (EGFR) peptide. Biomed Opt Express 2016;7:3163-9. [PMID: 27699089 DOI: 10.1364/BOE.7.003163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
72 Klintmalm GB, Nashan B. The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant. 2014;2014:845438. [PMID: 24719752 DOI: 10.1155/2014/845438] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
73 Hirschenberger M, Hunszinger V, Sparrer KMJ. Implications of Innate Immunity in Post-Acute Sequelae of Non-Persistent Viral Infections. Cells 2021;10:2134. [PMID: 34440903 DOI: 10.3390/cells10082134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 van Dijk F, Olinga P, Poelstra K, Beljaars L. Targeted Therapies in Liver Fibrosis: Combining the Best Parts of Platelet-Derived Growth Factor BB and Interferon Gamma. Front Med (Lausanne). 2015;2:72. [PMID: 26501061 DOI: 10.3389/fmed.2015.00072] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
75 Lopez-Lastra S, Di Santo JP. Modeling Natural Killer Cell Targeted Immunotherapies. Front Immunol 2017;8:370. [PMID: 28405194 DOI: 10.3389/fimmu.2017.00370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
76 Cho YY, Yu SJ, Lee HW, Kim DY, Kang W, Paik YH, Sung PS, Bae SH, Park SC, Doh YS, Kim KM, Jang ES, Kim IH, Kim W, Kim YJ. Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. J Hepatocell Carcinoma 2021;8:613-23. [PMID: 34169044 DOI: 10.2147/JHC.S304439] [Reference Citation Analysis]
77 Rosiak G, Podgorska J, Rosiak E, Cieszanowski A. Comparison of LI-RADS v.2017 and ESGAR Guidelines Imaging Criteria in HCC Diagnosis Using MRI with Hepatobiliary Contrast Agents. Biomed Res Int 2018;2018:7465126. [PMID: 30105242 DOI: 10.1155/2018/7465126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
78 Hesketh RL, Zhu AX, Oklu R. Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care? Am J Clin Oncol 2015;38:431-6. [PMID: 25238287 DOI: 10.1097/COC.0000000000000123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
79 Chávez-López MG, Zúñiga-García V, Pérez-Carreón JI, Avalos-Fuentes A, Escobar Y, Camacho J. Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma. Biologics 2016;10:139-48. [PMID: 27703327 DOI: 10.2147/BTT.S87402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
80 Wang Q, Bin C, Xue Q, Gao Q, Huang A, Wang K, Tang N. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell Death Dis 2021;12:426. [PMID: 33931597 DOI: 10.1038/s41419-021-03718-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
81 Dooley S, ten Dijke P. TGF-β in progression of liver disease. Cell Tissue Res. 2012;347:245-256. [PMID: 22006249 DOI: 10.1007/s00441-011-1246-y] [Cited by in Crossref: 409] [Cited by in F6Publishing: 419] [Article Influence: 40.9] [Reference Citation Analysis]
82 Zheng J, Hoffman KL, Chen JS, Shivappa N, Sood A, Browman GJ, Dirba DD, Hanash S, Wei P, Hebert JR, Petrosino JF, Schembre SM, Daniel CR. Dietary inflammatory potential in relation to the gut microbiome: results from a cross-sectional study. Br J Nutr 2020;124:931-42. [PMID: 32475373 DOI: 10.1017/S0007114520001853] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
83 Huang W, Gao F, Li K, Wang W, Lai YR, Tang SH, Yang DH. Decaprenyl diphosphate synthase subunit 2 as a prognosis factor in hepatocellular carcinoma. World J Gastroenterol 2015; 21(10): 3055-3065 [PMID: 25780306 DOI: 10.3748/wjg.v21.i10.3055] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
84 Liu J, Zhai C, Liu D, Liu J. The Long Noncoding RNA LOXL1-AS1 Promotes the Proliferation, Migration, and Invasion in Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2020;2020:4182092. [PMID: 33381389 DOI: 10.1155/2020/4182092] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Zhao M, Dong L, Liu Z, Yang S, Wu W, Lin J. In vivo fluorescence imaging of hepatocellular carcinoma using a novel GPC3-specific aptamer probe. Quant Imaging Med Surg 2018;8:151-60. [PMID: 29675356 DOI: 10.21037/qims.2018.01.09] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
86 Lu WL, Ren HY, Liang C, Zhang YY, Xu J, Pan ZQ, Liu XM, Wu ZH, Fang ZQ. Akebia trifoliate (Thunb.) Koidz Seed Extract Inhibits the Proliferation of Human Hepatocellular Carcinoma Cell Lines via Inducing Endoplasmic Reticulum Stress. Evid Based Complement Alternat Med. 2014;2014:192749. [PMID: 25389441 DOI: 10.1155/2014/192749] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
87 Adler M, Larocca L, Trovato FM, Marcinkowski H, Pasha Y, Taylor-Robinson SD. Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study. HPB (Oxford) 2016;18:678-83. [PMID: 27485062 DOI: 10.1016/j.hpb.2016.05.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
88 Zhao M, Liu Z, Dong L, Zhou H, Yang S, Wu W, Lin J. A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma. Int J Nanomedicine. 2018;13:4433-4443. [PMID: 30122918 DOI: 10.2147/ijn.s168268] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
89 Aljumah AA, Kuriry H, AlZunaitan M, Al Ghobain M, Al Muaikeel M, Al Olayan A, Azzumeea F, Almutairi B, AlAlwan A, AlGhamdi H. Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience. Gastroenterol Res Pract 2016;2016:1989045. [PMID: 27525001 DOI: 10.1155/2016/1989045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
90 Hu J, Song C, Duan B, Zhang X, Li D, Zhu L, Gao H. LncRNA-SVUGP2 suppresses progression of hepatocellular carcinoma. Oncotarget. 2017;8:97835-97850. [PMID: 29228655 DOI: 10.18632/oncotarget.18279] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
91 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015; 7(3): 362-376 [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 12.3] [Reference Citation Analysis]
92 Zidan A, Scheuerlein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon. 2012;12:e6894. [PMID: 23233864 DOI: 10.5812/hepatmon.6894] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
93 Deng R, Zhao X, Qu Y, Chen C, Zhu C, Zhang H, Yuan H, Jin H, Liu X, Wang Y, Chen Q, Huang J, Yu J. Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development. Oncotarget 2015;6:9355-69. [PMID: 25823821 DOI: 10.18632/oncotarget.3323] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
94 Teng CF, Li TC, Wang T, Wu TH, Wang J, Wu HC, Shyu WC, Su IJ, Jeng LB. Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant. J Hepatocell Carcinoma 2020;7:385-401. [PMID: 33365286 DOI: 10.2147/JHC.S282818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Jiang P, Cao J, Bai WH. Lentivirus-Mediated siRNA Targeting ER-α Inhibits Tumorigenesis and Induces Apoptosis in Hepatocarcinoma Cells. Biomed Res Int 2015;2015:490681. [PMID: 26413526 DOI: 10.1155/2015/490681] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
96 Appel-da-Silva MC, Miozzo SADS, Dossin IA, Tovo CV, Branco F, Mattos AA. Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study. World J Gastroenterol 2016; 22(46): 10219-10225 [PMID: 28028370 DOI: 10.3748/wjg.v22.i46.10219] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
97 Yu M, Xu W, Jie Y, Pang J, Huang S, Cao J, Gong J, Li X, Chong Y. Identification and validation of three core genes in p53 signaling pathway in hepatitis B virus-related hepatocellular carcinoma. World J Surg Oncol 2021;19:66. [PMID: 33685467 DOI: 10.1186/s12957-021-02174-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
98 Li MM, Tang YQ, Gong YF, Cheng W, Li HL, Kong FE, Zhu WJ, Liu SS, Huang L, Guan XY, Ma NF, Liu M. Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma. BMC Cancer 2019;19:851. [PMID: 31462277 DOI: 10.1186/s12885-019-6041-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
99 Figarola JL, Singhal J, Tompkins JD, Rogers GW, Warden C, Horne D, Riggs AD, Awasthi S, Singhal SS. SR4 Uncouples Mitochondrial Oxidative Phosphorylation, Modulates AMP-dependent Kinase (AMPK)-Mammalian Target of Rapamycin (mTOR) Signaling, and Inhibits Proliferation of HepG2 Hepatocarcinoma Cells. J Biol Chem 2015;290:30321-41. [PMID: 26534958 DOI: 10.1074/jbc.M115.686352] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
100 Peng C, Xiao X, Kang B, He S, Li J. Serum secreted frizzled-related protein 5 levels differentially decrease in patients with hepatitis B virus-associated chronic infection and hepatocellular carcinoma. Oncol Lett. 2014;8:1340-1344. [PMID: 25120720 DOI: 10.1007/s13277-014-1767-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
101 Wang BG, Jiang LY, Xu Q. Comprehensive assessment for miRNA polymorphisms in hepatocellular cancer risk: a systematic review and meta-analysis. Biosci Rep 2018;38:BSR20180712. [PMID: 29976775 DOI: 10.1042/BSR20180712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
102 Teng CF, Tsai HW, Li TC, Wang T, Wang J, Shyu WC, Wu HC, Su IJ, Jeng LB. Detection of hepatitis B virus pre-S mutants in plasma by a next-generation sequencing-based platform determines their patterns in liver tissues. PLoS One 2020;15:e0234773. [PMID: 32559248 DOI: 10.1371/journal.pone.0234773] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
103 Huang JF, Jiang HY, Cai H, Liu Y, Zhu YQ, Lin SS, Hu TT, Wang TT, Yang WJ, Xiao B, Sun SH, Ma LY, Yin HR, Wang F. Genome-wide screening identifies oncofetal lncRNA Ptn-dt promoting the proliferation of hepatocellular carcinoma cells by regulating the Ptn receptor. Oncogene. 2019;38:3428-3445. [PMID: 30643194 DOI: 10.1038/s41388-018-0643-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
104 Wang W, Dang S, Li Y, Sun M, Jia X, Wang R, Liu J. hOGG1 Ser326Cys polymorphism and risk of hepatocellular carcinoma among East Asians: a meta-analysis. PLoS One 2013;8:e60178. [PMID: 23577090 DOI: 10.1371/journal.pone.0060178] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
105 Gu Y, Lian Y, Zheng Q, Huang Z, Gu L, Bi Y, Li J, Huang Y, Wu Y, Chen L, Huang Y. Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B. BMC Infect Dis 2020;20:509. [PMID: 32664850 DOI: 10.1186/s12879-020-05233-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Zhang J, Li H, Huang Z, He Y, Zhou X, Huang T, Dai P, Duan D, Ma X, Yin Q, Wang X, Liu H, Chen S, Zou F, Chen X. Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells. Cell Stress Chaperones 2016;21:339-48. [PMID: 26786409 DOI: 10.1007/s12192-015-0664-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
107 Cao L, Xie B, Yang X, Liang H, Jiang X, Zhang D, Xue P, Chen D, Shao Z. MiR-324-5p Suppresses Hepatocellular Carcinoma Cell Invasion by Counteracting ECM Degradation through Post-Transcriptionally Downregulating ETS1 and SP1. PLoS One 2015;10:e0133074. [PMID: 26177288 DOI: 10.1371/journal.pone.0133074] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
108 Kim Y, Ejaz A, Tayal A, Spolverato G, Bridges JF, Anders RA, Pawlik TM. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer 2014;120:3058-65. [PMID: 24917245 DOI: 10.1002/cncr.28843] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
109 Lam IF, Huang M, Chang MD, Yao PW, Chou YT, Ng SK, Tsai YL, Lin YC, Zhang YF, Yang XY, Lai YK. Identification of anti-HBV activities in Paeonia suffruticosa Andr. using GRP78 as a drug target on Herbochip®. Chin Med 2017;12:11. [PMID: 28450884 DOI: 10.1186/s13020-017-0132-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
110 Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol 2017;8:229-42. [PMID: 28480063 DOI: 10.21037/jgo.2017.03.14] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 15.0] [Reference Citation Analysis]
111 Chang L, Li K, Guo T. miR-26a-5p suppresses tumor metastasis by regulating EMT and is associated with prognosis in HCC. Clin Transl Oncol 2017;19:695-703. [PMID: 27864783 DOI: 10.1007/s12094-016-1582-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
112 Keshavarz-Fathi M, Rezaei N. Cancer Immunoprevention: Current Status and Future Directions. Arch Immunol Ther Exp (Warsz) 2021;69:3. [PMID: 33638703 DOI: 10.1007/s00005-021-00604-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Teng CF, Huang HY, Li TC, Shyu WC, Wu HC, Lin CY, Su IJ, Jeng LB. A Next-Generation Sequencing-Based Platform for Quantitative Detection of Hepatitis B Virus Pre-S Mutants in Plasma of Hepatocellular Carcinoma Patients. Sci Rep. 2018;8:14816. [PMID: 30287845 DOI: 10.1038/s41598-018-33051-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
114 Cheng Z, Lin P, Cheng N. HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. Front Med (Lausanne) 2021;8:713981. [PMID: 34676223 DOI: 10.3389/fmed.2021.713981] [Reference Citation Analysis]
115 Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, Scholz A. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia. 2013;15:1161-1171. [PMID: 24204195 DOI: 10.1593/neo.13812] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
116 Chan FK, Cheng KC. Laparoscopic liver resection: western versus eastern experience. Chin J Cancer Res 2014;26:243-4. [PMID: 25035649 DOI: 10.3978/j.issn.1000-9604.2014.06.16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013;144:1024-30. [PMID: 23333348 DOI: 10.1053/j.gastro.2013.01.021] [Cited by in Crossref: 125] [Cited by in F6Publishing: 121] [Article Influence: 15.6] [Reference Citation Analysis]
118 Navas MC, Suarez I, Carreño A, Uribe D, Rios WA, Cortes-Mancera F, Martel G, Vieco B, Lozano D, Jimenez C, Gouas D, Osorio G, Hoyos S, Restrepo JC, Correa G, Jaramillo S, Lopez R, Bravo LE, Arbelaez MP, Scoazec JY, Abedi-Ardekani B, Santella RM, Chemin I, Hainaut P. Hepatitis B and Hepatitis C Infection Biomarkers and TP53 Mutations in Hepatocellular Carcinomas from Colombia. Hepat Res Treat 2011;2011:582945. [PMID: 22114738 DOI: 10.1155/2011/582945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
119 Feng Q, Chi Y, Liu Y, Zhang L, Liu Q. Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies. J Cancer Res Clin Oncol 2015;141:1-9. [PMID: 24889505 DOI: 10.1007/s00432-014-1708-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
120 Movahedi A, Basir R, Rahmat A, Charaffedine M, Othman F. Remarkable Anticancer Activity of Teucrium polium on Hepatocellular Carcinogenic Rats. Evid Based Complement Alternat Med 2014;2014:726724. [PMID: 25197311 DOI: 10.1155/2014/726724] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
121 Koschny R, Brost S, Hinz U, Sykora J, Batke EM, Singer S, Breuhahn K, Stremmel W, Walczak H, Schemmer P, Schirmacher P, Ganten TM. Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer 2013;13:532. [PMID: 24209510 DOI: 10.1186/1471-2407-13-532] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
122 Yan Y, Jiang K, Liu P, Zhang X, Dong X, Gao J, Liu Q, Barr MP, Zhang Q, Hou X, Meng S, Gong P. Bafilomycin A1 induces caspase-independent cell death in hepatocellular carcinoma cells via targeting of autophagy and MAPK pathways. Sci Rep 2016;6:37052. [PMID: 27845389 DOI: 10.1038/srep37052] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 8.4] [Reference Citation Analysis]
123 Sellers CM, Uhlig J, Ludwig JM, Taddei T, Stein SM, Lim JK, Kim HS. The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance. Cancer Med 2019;8:5948-58. [PMID: 31436905 DOI: 10.1002/cam4.2251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
124 Yu W, Huang C, Wang Q, Huang T, Ding Y, Ma C, Ma H, Chen W. MEF2 transcription factors promotes EMT and invasiveness of hepatocellular carcinoma through TGF-β1 autoregulation circuitry. Tumour Biol. 2014;35:10943-10951. [PMID: 25087096 DOI: 10.1007/s13277-014-2403-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
125 Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 2018;23:586-93. [PMID: 29487225 DOI: 10.1634/theoncologist.2017-0479] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
126 Yang L, Wang Q, Cui T, Huang J, Jin H. Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis. Can J Gastroenterol Hepatol 2021;2021:9996358. [PMID: 34513751 DOI: 10.1155/2021/9996358] [Reference Citation Analysis]
127 Teng CF, Li TC, Wang T, Liao DC, Wen YH, Wu TH, Wang J, Wu HC, Shyu WC, Su IJ, Jeng LB. Increased infiltration of regulatory T cells in hepatocellular carcinoma of patients with hepatitis B virus pre-S2 mutant. Sci Rep 2021;11:1136. [PMID: 33441885 DOI: 10.1038/s41598-020-80935-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
128 Hu X, Feng Y, Sun L, Qu L, Sun C. Roles of microRNA-330 and Its Target Gene ING4 in the Development of Aggressive Phenotype in Hepatocellular Carcinoma Cells. Dig Dis Sci. 2017;62:715-722. [PMID: 28050784 DOI: 10.1007/s10620-016-4429-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
129 Huang BS, Tsang NM, Lin SM, Lin DY, Lien JM, Lin CC, Chen WT, Chen WY, Hong JH. High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities. Oncol Lett 2013;6:1514-20. [PMID: 24179551 DOI: 10.3892/ol.2013.1582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
130 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 45] [Article Influence: 20.0] [Reference Citation Analysis]
131 He X, Qu F, Zhou F, Zhou X, Chen Y, Guo X, Li J, Huang Q, Yang Y, Lyu Z, Zhang H, Xing J. High leukocyte mtDNA content contributes to poor prognosis through ROS-mediated immunosuppression in hepatocellular carcinoma patients. Oncotarget 2016;7:22834-45. [PMID: 26985767 DOI: 10.18632/oncotarget.8071] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
132 Peng C, Xiao X, Kang B, He S, Li J. Serum secreted frizzled-related protein 5 Levels differentially decrease in patients with hepatitis B virus-associated chronic infection and hepatocellular carcinoma. Oncol Lett. 2014;8:1340-1344. [PMID: 25120720 DOI: 10.3892/ol.2014.2256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
133 Saleh D, Gomaa W, Al-Maghrabi J. A Rare Concomitant Oncocytic Adrenocortical Neoplasm and Hepatocellular Carcinoma over a Four-year Duration: A Case Report and Review of Literature. Case Rep Pathol 2019;2019:9137120. [PMID: 31772806 DOI: 10.1155/2019/9137120] [Reference Citation Analysis]
134 Zhang W, Jiang R, Hou J, Sun B. Clinicopathological features and prognostic factors of young patients with surgically treated liver cancer. Medicine (Baltimore) 2015;94:e684. [PMID: 25816040 DOI: 10.1097/MD.0000000000000684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
135 Ling TC, Kang JI, Bush DA, Slater JD, Yang GY. Proton therapy for hepatocellular carcinoma. Chin J Cancer Res 2012;24:361-7. [PMID: 23359779 DOI: 10.3978/j.issn.1000-9604.2012.10.09] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
136 Xu Q, Tu J, Dou C, Zhang J, Yang L, Liu X, Lei K, Liu Z, Wang Y, Li L, Bao H, Wang J, Tu K. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma. Mol Cancer. 2017;16:178. [PMID: 29262861 DOI: 10.1186/s12943-017-0748-y] [Cited by in Crossref: 59] [Cited by in F6Publishing: 67] [Article Influence: 14.8] [Reference Citation Analysis]
137 Pace C, Nardone V, Roma S, Chegai F, Toti L, Manzia TM, Tisone G, Orlacchio A. Evaluation of Contrast-Enhanced Intraoperative Ultrasound in the Detection and Management of Liver Lesions in Patients with Hepatocellular Carcinoma. J Oncol 2019;2019:6089340. [PMID: 31467539 DOI: 10.1155/2019/6089340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Yang W, Yan K, Wu GX, Wu W, Fu Y, Lee JC, Zhang ZY, Wang S, Chen MH. Radiofrequency ablation of hepatocellular carcinoma in difficult locations: Strategies and long-term outcomes. World J Gastroenterol 2015; 21(5): 1554-1566 [PMID: 25663774 DOI: 10.3748/wjg.v21.i5.1554] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
139 Huang X, Sun L, Wen S, Deng D, Wan F, He X, Tian L, Liang L, Wei C, Gao K, Fu Q, Li Y, Jiang J, Zhai R, He M. RNA sequencing of plasma exosomes revealed novel functional long noncoding RNAs in hepatocellular carcinoma. Cancer Sci. 2020;111:3338-3349. [PMID: 32506598 DOI: 10.1111/cas.14516] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
140 Chen Y, Tian Z. HBV-Induced Immune Imbalance in the Development of HCC. Front Immunol 2019;10:2048. [PMID: 31507621 DOI: 10.3389/fimmu.2019.02048] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 18.0] [Reference Citation Analysis]
141 Kohno T, Morishita A, Iwama H, Fujita K, Tani J, Takuma K, Nakahara M, Oura K, Tadokoro T, Nomura T, Yoneyama H, Kato K, Okano K, Suzuki Y, Nishiyama A, Himoto T, Masaki T. Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma. Oncol Lett 2020;20:1727-33. [PMID: 32724415 DOI: 10.3892/ol.2020.11696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
142 Felizardo RJ, Câmara NO. Hepatocellular carcinoma and food contamination: Ochratoxin A as a great prompter. World J Gastroenterol 2013; 19(24): 3723-3725 [PMID: 23840111 DOI: 10.3748/wjg.v19.i24.3723] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
143 Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol. 2018;6:69-78. [PMID: 29607307 DOI: 10.14218/jcth.2017.00031] [Cited by in Crossref: 97] [Cited by in F6Publishing: 76] [Article Influence: 24.3] [Reference Citation Analysis]
144 Huppert LA, Gordan JD, Kelley RK. Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2020;15:53-8. [PMID: 32226615 DOI: 10.1002/cld.879] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
145 Ji C. New Insights into the Pathogenesis of Alcohol-Induced ER Stress and Liver Diseases. Int J Hepatol. 2014;2014:513787. [PMID: 24868470 DOI: 10.1155/2014/513787] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
146 Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int. 2013;2013:136106. [PMID: 23762823 DOI: 10.1155/2013/136106] [Cited by in Crossref: 129] [Cited by in F6Publishing: 170] [Article Influence: 16.1] [Reference Citation Analysis]
147 Arteel GE. Liver-lung axes in alcohol-related liver disease. Clin Mol Hepatol 2020;26:670-6. [PMID: 33053938 DOI: 10.3350/cmh.2020.0174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials 2014;15:474. [PMID: 25472660 DOI: 10.1186/1745-6215-15-474] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
149 Li Y, Zhang T, Qin S, Wang R, Li Y, Zhou Z, Chen Y, Wu Q, Su F. Effects of UPF1 expression on EMT process by targeting E‑cadherin, N‑cadherin, Vimentin and Twist in a hepatocellular carcinoma cell line. Mol Med Rep 2019;19:2137-43. [PMID: 30628676 DOI: 10.3892/mmr.2019.9838] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
150 Guerrero-Misas M, Rodríguez-Perálvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 2015; 7(4): 649-661 [PMID: 25866602 DOI: 10.4254/wjh.v7.i4.649] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
151 Welte S, Urbanik T, Elßner C, Kautz N, Koehler BC, Waldburger N, Bermejo JL, Pinna F, Weiss KH, Schemmer P, Jaeger D, Longerich T, Breuhahn K, Schulze-Bergkamen H. Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma. PLoS One 2014;9:e110591. [PMID: 25329885 DOI: 10.1371/journal.pone.0110591] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
152 Chelliah AR, Radhi JM. Hepatocellular Carcinoma with Prominent Intracytoplasmic Inclusions: A Report of Two Cases. Case Reports Hepatol 2016;2016:2032714. [PMID: 27818805 DOI: 10.1155/2016/2032714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
153 Dong G, Zhang S, Shen S, Sun L, Wang X, Wang H, Wu J, Liu T, Wang C, Wang H, Lu T, Rao B, Ren Z. SPATS2, negatively regulated by miR-145-5p, promotes hepatocellular carcinoma progression through regulating cell cycle. Cell Death Dis 2020;11:837. [PMID: 33037180 DOI: 10.1038/s41419-020-03039-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
154 Teng CF, Wang T, Wu TH, Lin JH, Shih FY, Shyu WC, Jeng LB. Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model. Ther Adv Med Oncol. 2020;12:1758835920922034. [PMID: 32565925 DOI: 10.1177/1758835920922034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
155 Nagahara T, Shiraha H, Sawahara H, Uchida D, Takeuchi Y, Iwamuro M, Kataoka J, Horiguchi S, Kuwaki T, Onishi H, Nakamura S, Takaki A, Nouso K, Yamamoto K. Hepatic stellate cells promote upregulation of epithelial cell adhesion molecule and epithelial-mesenchymal transition in hepatic cancer cells. Oncol Rep 2015;34:1169-77. [PMID: 26165819 DOI: 10.3892/or.2015.4126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
156 Chang L, Li C, Lan T, Wu L, Yuan Y, Liu Q, Liu Z. Decreased expression of long non-coding RNA GAS5 indicates a poor prognosis and promotes cell proliferation and invasion in hepatocellular carcinoma by regulating vimentin. Mol Med Rep. 2016;13:1541-1550. [PMID: 26707238 DOI: 10.3892/mmr.2015.4716] [Cited by in Crossref: 70] [Cited by in F6Publishing: 84] [Article Influence: 11.7] [Reference Citation Analysis]
157 Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH, Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM, Chow PK; Asia-Pacific Hepatocellular Carcinoma Trials Group. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. BMC Cancer 2016;16:856. [PMID: 27821083 DOI: 10.1186/s12885-016-2868-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
158 Wu Y, Xiong Q, Li S, Yang X, Ge F. Integrated Proteomic and Transcriptomic Analysis Reveals Long Noncoding RNA HOX Transcript Antisense Intergenic RNA (HOTAIR) Promotes Hepatocellular Carcinoma Cell Proliferation by Regulating Opioid Growth Factor Receptor (OGFr). Mol Cell Proteomics 2018;17:146-59. [PMID: 29079719 DOI: 10.1074/mcp.RA117.000277] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
159 Zhu M, Liang Z, Pan J, Zhang X, Xue R, Cao G, Hu X, Gong C. Hepatocellular carcinoma progression mediated by hepatitis B virus-encoded circRNA HBV_circ_1 through interaction with CDK1. Mol Ther Nucleic Acids 2021;25:668-82. [PMID: 34589285 DOI: 10.1016/j.omtn.2021.08.011] [Reference Citation Analysis]
160 Zhen L, Ning G, Wu L, Zheng Y, Yang F, Chen T, Xu W, Liu Y, Xie C, Peng L. Prognostic value of aberrantly expressed methylation genes in human hepatocellular carcinoma. Biosci Rep 2020;40:BSR20192593. [PMID: 32955083 DOI: 10.1042/BSR20192593] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Ouyang X, Wang Z, Yao L, Zhang G. Elevated CELSR3 expression is associated with hepatocarcinogenesis and poor prognosis. Oncol Lett 2020;20:1083-92. [PMID: 32724347 DOI: 10.3892/ol.2020.11671] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
162 Chie WC, Yu F, Li M, Baccaglini L, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-Kadhimi G. Quality of life changes in patients undergoing treatment for hepatocellular carcinoma. Qual Life Res. 2015;24:2499-2506. [PMID: 25943170 DOI: 10.1007/s11136-015-0985-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
163 Young K, Fidelman N, Yao FY, Hills NK, Kohi MP, Kolli KP, Taylor AG, Kerlan RK Jr. Implications of discordant findings between hepatic angiography and cross-sectional imaging in transplant candidates with hepatocellular carcinoma. Liver Transpl 2015;21:454-67. [PMID: 25678220 DOI: 10.1002/lt.24090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
164 Xie H, Wang H, An W, Ma W, Qi R, Yang B, Liu C, Gao Y, Xu B, Wang W. The efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma in a cohort of 487 patients. PLoS One. 2014;9:e89081. [PMID: 24586515 DOI: 10.1371/journal.pone.0089081] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
165 Lv C, Wang S, Lin L, Wang C, Zeng K, Meng Y, Sun G, Wei S, Liu Y, Zhao Y. USP14 maintains HIF1-α stabilization via its deubiquitination activity in hepatocellular carcinoma. Cell Death Dis 2021;12:803. [PMID: 34420039 DOI: 10.1038/s41419-021-04089-6] [Reference Citation Analysis]
166 Dai M, Yang YW, Guo WH, Wang FL, Xiao GM, Li YM, Yang HZ. Addition and Subtraction Theory of TCM Using Xiao-Chaihu-Decoction and Naturopathy in Predicting Survival Outcomes of Primary Liver Cancer Patients: A Prospective Cohort Study. Evid Based Complement Alternat Med 2016;2016:4723530. [PMID: 27843477 DOI: 10.1155/2016/4723530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
167 Li K, Song Y, Qin L, Li A, Jiang S, Ren L, Zang C, Sun J, Zhao Y, Zhang Y. A CpG Methylation Signature as a Potential Marker for Early Diagnosis of Hepatocellular Carcinoma From HBV-Related Liver Disease Using Multiplex Bisulfite Sequencing. Front Oncol 2021;11:756326. [PMID: 34745991 DOI: 10.3389/fonc.2021.756326] [Reference Citation Analysis]
168 Huang Q, Lei H, Ding L, Wang Y. Stimulated phospholipid synthesis is key for hepatitis B virus replications. Sci Rep 2019;9:12989. [PMID: 31506451 DOI: 10.1038/s41598-019-49367-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
169 Xie R, Xu J, Wen G, Jin H, Liu X, Yang Y, Ji B, Jiang Y, Song P, Dong H, Tuo B. The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP. J Biol Chem 2014;289:19137-49. [PMID: 24847054 DOI: 10.1074/jbc.M113.540047] [Cited by in Crossref: 51] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
170 Toomey PG, Vohra NA, Ghansah T, Sarnaik AA, Pilon-Thomas SA. Immunotherapy for gastrointestinal malignancies. Cancer Control 2013;20:32-42. [PMID: 23302905 DOI: 10.1177/107327481302000106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
171 Ge T, Shen Q, Wang N, Zhang Y, Ge Z, Chu W, Lv X, Zhao F, Zhao W, Fan J, Qin W. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma. Med Oncol 2015;32. [DOI: 10.1007/s12032-014-0367-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
172 Feng XJ, Pan Q, Wang SM, Pan YC, Wang Q, Zhang HH, Zhu MH, Zhang SH. MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. Tumour Biol 2016;37:11457-67. [PMID: 27010469 DOI: 10.1007/s13277-016-5022-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
173 Pollack HJ, Kwon SC, Wang SH, Wyatt LC, Trinh-Shevrin C. Chronic hepatitis B and liver cancer risks among Asian immigrants in New York City: Results from a large, community-based screening, evaluation, and treatment program. Cancer Epidemiol Biomarkers Prev. 2014;23:2229-2239. [PMID: 25368398 DOI: 10.1158/1055-9965.epi-14-0491] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
174 Ratti F, Barkhatov LI, Tomassini F, Cipriani F, Kazaryan AM, Edwin B, Abu Hilal M, Troisi RI, Aldrighetti L. Learning curve of self-taught laparoscopic liver surgeons in left lateral sectionectomy: results from an international multi-institutional analysis on 245 cases. Surg Endosc 2016;30:3618-29. [PMID: 26572765 DOI: 10.1007/s00464-015-4665-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
175 Liu Z, Yu Y, Huang Z, Kong Y, Hu X, Xiao W, Quan J, Fan X. CircRNA-5692 inhibits the progression of hepatocellular carcinoma by sponging miR-328-5p to enhance DAB2IP expression. Cell Death Dis 2019;10:900. [PMID: 31776329 DOI: 10.1038/s41419-019-2089-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 68] [Article Influence: 27.0] [Reference Citation Analysis]
176 Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015; 7(10): 1412-1420 [PMID: 26052386 DOI: 10.4254/wjh.v7.i10.1412] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
177 Zhu S, Cao S, Yang W, Che J, Li D, Pei R, Ding Y. The Maturation of Tumor Suppressor miR-497 in Hepatocellular Carcinoma is Inhibited by Oncogenic circRNA SCARB1. Cancer Manag Res 2021;13:5751-9. [PMID: 34305409 DOI: 10.2147/CMAR.S304125] [Reference Citation Analysis]
178 Liu Z, Dai H, Jia G, Li Y, Liu X, Ren W. Insufficient radiofrequency ablation promotes human hepatoma SMMC7721 cell proliferation by stimulating vascular endothelial growth factor overexpression. Oncol Lett 2015;9:1893-6. [PMID: 25789063 DOI: 10.3892/ol.2015.2966] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
179 Carr BI, Lin CY, Lu SN. Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol 2014;41:415-21. [PMID: 25023358 DOI: 10.1053/j.seminoncol.2014.04.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
180 Qin XY, Wei F, Tanokura M, Ishibashi N, Shimizu M, Moriwaki H, Kojima S. The effect of acyclic retinoid on the metabolomic profiles of hepatocytes and hepatocellular carcinoma cells. PLoS One 2013;8:e82860. [PMID: 24376596 DOI: 10.1371/journal.pone.0082860] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
181 Liu L, Wang Z, Jiang S, Shao B, Liu J, Zhang S, Zhou Y, Zhou Y, Zhang Y. Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis. PLoS One 2013;8:e64261. [PMID: 23741309 DOI: 10.1371/journal.pone.0064261] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 8.1] [Reference Citation Analysis]
182 Hao X, Chen Y, Bai L, Wei H, Sun R, Tian Z. HBsAg-specific CD8+ T cells as an indispensable trigger to induce murine hepatocellular carcinoma. Cell Mol Immunol 2021;18:128-37. [PMID: 31767976 DOI: 10.1038/s41423-019-0330-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
183 Anfuso B, Tiribelli C, Sukowati CH. Recent insights into hepatic cancer stem cells. Hepatol Int 2014;8 Suppl 2:458-63. [PMID: 26201324 DOI: 10.1007/s12072-013-9498-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
184 Fujita K, Iwama H, Miyoshi H, Tani J, Oura K, Tadokoro T, Sakamoto T, Nomura T, Morishita A, Yoneyama H, Masaki T. Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol 2016; 22(27): 6100-6113 [PMID: 27468203 DOI: 10.3748/wjg.v22.i27.6100] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
185 Chouhan S, Singh S, Athavale D, Ramteke P, Pandey V, Joseph J, Mohan R, Shetty PK, Bhat MK. Glucose induced activation of canonical Wnt signaling pathway in hepatocellular carcinoma is regulated by DKK4. Sci Rep 2016;6:27558. [PMID: 27272409 DOI: 10.1038/srep27558] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
186 Ntagirabiri R, Munezero B, Kaze H, Ndirahisha E, Manirakiza S. [Incidence of hepatocellular carcinoma in chronic infection with hepatitis B]. Pan Afr Med J 2015;20:167. [PMID: 26113910 DOI: 10.11604/pamj.2015.20.167.6227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
187 Brito AF, Abrantes AM, Ribeiro M, Oliveira R, Casalta-Lopes J, Gonçalves AC, Sarmento-Ribeiro AB, Tralhão JG, Botelho MF. Fluorine-18 Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma: Correlation with Glucose Transporters and p53 Expression. J Clin Exp Hepatol 2015;5:183-9. [PMID: 26628835 DOI: 10.1016/j.jceh.2015.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
188 Hu Z, Yang A, Su G, Zhao Y, Wang Y, Chai X, Tu P. Huaier restrains proliferative and invasive potential of human hepatoma SKHEP-1 cells partially through decreased Lamin B1 and elevated NOV. Sci Rep 2016;6:31298. [PMID: 27503760 DOI: 10.1038/srep31298] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
189 Msyamboza KP, Dzamalala C, Mdokwe C, Kamiza S, Lemerani M, Dzowela T, Kathyola D. Burden of cancer in Malawi; common types, incidence and trends: National population-based cancer registry. BMC Res Notes. 2012;5:149. [PMID: 22424105 DOI: 10.1186/1756-0500-5-149] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 8.0] [Reference Citation Analysis]
190 Ewald F, Nörz D, Grottke A, Bach J, Herzberger C, Hofmann BT, Nashan B, Jücker M. Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma. J Cancer 2015;6:1195-205. [PMID: 26535060 DOI: 10.7150/jca.12452] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
191 Barathan M, Mariappan V, Shankar EM, Abdullah BJ, Goh KL, Vadivelu J. Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases. Cell Death Dis. 2013;4:e697. [PMID: 23807226 DOI: 10.1038/cddis.2013.219] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
192 Groeschl RT, Hong JC, Christians KK, Turaga KK, Tsai S, Pilgrim CH, Gamblin TC. Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival. HPB (Oxford) 2013;15:794-802. [PMID: 23782341 DOI: 10.1111/hpb.12134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
193 Matsumoto K, Wu Y, Kitazawa T, Fujita S, Seto K, Hasegawa T. Cost of illness of hepatocellular carcinoma in Japan: A time trend and future projections. PLoS One 2018;13:e0199188. [PMID: 29920556 DOI: 10.1371/journal.pone.0199188] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
194 Wu H, Pan L, Gao C, Xu H, Li Y, Zhang L, Ma L, Meng L, Sun X, Qin H. Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway. Molecules 2019;24:E1993. [PMID: 31137633 DOI: 10.3390/molecules24101993] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
195 Song L, Zhang W, Chang Z, Pan Y, Zong H, Fan Q, Wang L. miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells. Med Sci Monit 2017;23:1741-50. [PMID: 28394882 DOI: 10.12659/msm.900296] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
196 Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155-2166. [PMID: 25752327 DOI: 10.1111/liv.12818] [Cited by in Crossref: 369] [Cited by in F6Publishing: 383] [Article Influence: 61.5] [Reference Citation Analysis]
197 Shen H, Zhou S, Lou Y, Gao Y, Cao S, Wu D, Li G. Microwave-Assisted Ablation Improves the Prognosis of Patients With Hepatocellular Carcinoma Undergoing Liver Resection. Technol Cancer Res Treat 2018;17:1533033818785980. [PMID: 29983095 DOI: 10.1177/1533033818785980] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
198 Dhamija E, Paul SB, Kedia S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Indian J Med Res. 2019;149:9-17. [PMID: 31115369 DOI: 10.4103/ijmr.ijmr_1456_17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
199 Kang HJ, Seol HS, Lee SE, Suh YA, Kim J, Jang SJ, Yu E. Guanabenz Acetate Induces Endoplasmic Reticulum Stress-Related Cell Death in Hepatocellular Carcinoma Cells. J Pathol Transl Med 2019;53:94-103. [PMID: 30646673 DOI: 10.4132/jptm.2019.01.14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
200 Cevik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol 2015; 21(1): 311-317 [PMID: 25574106 DOI: 10.3748/wjg.v21.i1.311] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
201 Chiu AP, Tschida BR, Lo LH, Moriarity BS, Rowlands DK, Largaespada DA, Keng VW. Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12157-12170 [PMID: 26576100 DOI: 10.3748/wjg.v21.i42.12157] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
202 Khan IM, Gjuka D, Jiao J, Song X, Wang Y, Wang J, Wei P, El-Serag HB, Marrero JA, Beretta L. A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila) 2021;14:667-74. [PMID: 33685927 DOI: 10.1158/1940-6207.CAPR-20-0600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Amr KS, Elmawgoud Atia HA, Elazeem Elbnhawy RA, Ezzat WM. Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma. Genes Dis 2017;4:215-21. [PMID: 30258925 DOI: 10.1016/j.gendis.2017.10.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
204 Zhang Y, Tao R, Wu SS, Xu CC, Wang JL, Chen J, Yu YS, Tang ZH, Chen XH, Zang GQ. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A. J Exp Clin Cancer Res 2018;37:116. [PMID: 29898761 DOI: 10.1186/s13046-018-0780-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
205 Morishita A, Iwama H, Fujihara S, Watanabe M, Fujita K, Tadokoro T, Ohura K, Chiyo T, Sakamoto T, Mimura S, Nomura T, Tani J, Yoneyama H, Okano K, Suzuki Y, Himoto T, Masaki T. Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next-generation sequencing. Oncol Lett 2018;15:528-32. [PMID: 29391887 DOI: 10.3892/ol.2017.7334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
206 Xi R, Kadur Lakshminarasimha Murthy P, Tung KL, Guy CD, Wan J, Li F, Wang Z, Li X, Varanko A, Rakhilin N, Xin Y, Liu B, Qian SB, Su L, Han Y, Shen X. SENP3-mediated host defense response contains HBV replication and restores protein synthesis. PLoS One 2019;14:e0209179. [PMID: 30640896 DOI: 10.1371/journal.pone.0209179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
207 Pancoska P, Lu SN, Carr BI. Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas. J Gastrointest Dig Syst 2013;Suppl 12:001. [PMID: 23956952 DOI: 10.4172/2161-069X.S12-001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
208 Yeesoonsang S, McNeil E, Virani S, Bilheem S, Pittayawonganon C, Jiraphongsa C, Sriplung H. Trends in Incidence of Two Major Subtypes of Liver and Bile Duct Cancer: Hepatocellular Carcinoma and Cholangiocarcinoma in Songkhla, Southern Thailand, 1989-2030. J Cancer Epidemiol 2018;2018:8267059. [PMID: 30675163 DOI: 10.1155/2018/8267059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
209 Chan SL, Johnson PJ, Mo F, Berhane S, Teng M, Chan AW, Poon MC, Lai PB, Yu S, Chan AT. International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chin J Cancer. 2014;33:481-491. [PMID: 25223914 DOI: 10.5732/cjc.014.10133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
210 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
211 Chen J, Zhu S, Tong L, Li J, Chen F, Han Y, Zhao M, Xiong W. Superparamagnetic iron oxide nanoparticles mediated (131)I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice. BMC Cancer. 2014;14:114. [PMID: 24555445 DOI: 10.1186/1471-2407-14-114] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
212 Shi L, Feng Y, Lin H, Ma R, Cai X. Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med. 2014;12:93. [PMID: 24708807 DOI: 10.1186/1479-5876-12-93] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 9.1] [Reference Citation Analysis]
213 Chang L, Li C, Guo T, Wang H, Ma W, Yuan Y, Liu Q, Ye Q, Liu Z. The human RNA surveillance factor UPF1 regulates tumorigenesis by targeting Smad7 in hepatocellular carcinoma. J Exp Clin Cancer Res 2016;35:8. [PMID: 26759305 DOI: 10.1186/s13046-016-0286-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 6.6] [Reference Citation Analysis]
214 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yang Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver. 2019;. [PMID: 31158948 DOI: 10.5009/gnl18546.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
215 Beier JI, Arteel GE. Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp Biol Med (Maywood) 2012;237:1-9. [PMID: 22238286 DOI: 10.1258/ebm.2011.011255] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
216 Liu Y, Xue X. Systematic review of peri-operative nutritional support for patients undergoing hepatobiliary surgery. Hepatobiliary Surg Nutr 2015;4:304-12. [PMID: 26605277 DOI: 10.3978/j.issn.2304-3881.2014.12.09] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
217 Jiang Y, Han Q, Zhao H, Zhang J. The Mechanisms of HBV-Induced Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:435-50. [PMID: 34046368 DOI: 10.2147/JHC.S307962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
218 Coia H, Ma N, He AR, Kallakury B, Berry DL, Permaul E, Makambi KH, Fu Y, Chung FL. Detection of a lipid peroxidation-induced DNA adduct across liver disease stages. Hepatobiliary Surg Nutr 2018;7:85-97. [PMID: 29744335 DOI: 10.21037/hbsn.2017.06.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
219 Park B, Jung KW, Oh CM, Choi KS, Suh M, Jun JK. Factors associated with alcohol consumption in hepatitis B carriers: a nationwide study in the Republic of Korea. PLoS One. 2014;9:e110144. [PMID: 25387237 DOI: 10.1371/journal.pone.0110144] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
220 Zhang L, He T, Yan Y, Zhang Y, Zhou X, Huang P, Kong Y, Xie M, Zhang L, Sun Q. Expression and Clinical Significance of the Novel Long Noncoding RNA ZNF674-AS1 in Human Hepatocellular Carcinoma. Biomed Res Int. 2016;2016:3608914. [PMID: 27896271 DOI: 10.1155/2016/3608914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
221 Ding WZ, Han GY, Jin HH, Zhan CF, Ji Y, Huang XL. Anti-IL-20 monoclonal antibody suppresses hepatocellular carcinoma progression. Oncol Lett 2018;16:6156-62. [PMID: 30333881 DOI: 10.3892/ol.2018.9402] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
222 Choi K, Joo H. Assessment of Gold Nanoparticles-Inhibited Cytochrome P450 3A4 Activity and Molecular Mechanisms Underlying Its Cellular Toxicity in Human Hepatocellular Carcinoma Cell Line C3A. Nanoscale Res Lett 2018;13:279. [PMID: 30203228 DOI: 10.1186/s11671-018-2684-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
223 Zhou Y, Li Y, Wang N, Li X, Zheng J, Ge L. UPF1 inhibits the hepatocellular carcinoma progression by targeting long non-coding RNA UCA1. Sci Rep 2019;9:6652. [PMID: 31040354 DOI: 10.1038/s41598-019-43148-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
224 Ye H, Tong J, Wu J, Xu X, Wu S, Tan B, Shi M, Wang J, Zhao W, Jiang H. Preclinical evaluation of recombinant human IFNα2b-containing magnetoliposomes for treating hepatocellular carcinoma. Int J Nanomedicine. 2014;9:4533-4550. [PMID: 25288882 DOI: 10.2147/IJN.S67228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
225 Zeng XC, Zhang L, Liao WJ, Ao L, Lin ZM, Kang W, Chen WN, Lin X. Screening and Identification of Potential Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma by Bioinformatics Analysis. Front Genet 2020;11:555537. [PMID: 33193629 DOI: 10.3389/fgene.2020.555537] [Reference Citation Analysis]
226 Cheng S, Yang J, Shen F, Zhou W, Wang Y, Cong W, Yang GS, Cheng H, Hu H, Gao C, Guo J, Li A, Meng Y, Jiang X, Yang Y, Qian G, Luo M, Hu B, Man X, Zhang B, Su C, Zhou F, Li N, Shi J, Wang M, Zheng Y, Guo W, Sun J, Wang H, Lau WY, Wu MC. Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement. Oncotarget 2016;7:40816-29. [PMID: 27027235 DOI: 10.18632/oncotarget.8386] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
227 Li H, Cui ML, Chen TY, Xie HY, Cui Y, Tu H, Chen FH, Ge C, Li JJ. Serum DLK1 is a potential prognostic biomarker in patients with hepatocellular carcinoma. Tumour Biol 2015;36:8399-404. [PMID: 26018510 DOI: 10.1007/s13277-015-3607-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
228 Sellers CM, Uhlig J, Ludwig JM, Pollak JS, Taddei TH, Stein SM, Lim JK, Kim HS. The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. Cancer Med 2021;10:5395-404. [PMID: 34318618 DOI: 10.1002/cam4.3573] [Reference Citation Analysis]
229 Sultana N, Rahman M, Myti S, Islam J, Mustafa MG, Nag K. A novel knowledge-derived data potentizing method revealed unique liver cancer-associated genetic variants. Hum Genomics 2019;13:30. [PMID: 31272500 DOI: 10.1186/s40246-019-0213-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
230 Shui L, Ren H, Yang X, Li J, Chen Z, Yi C, Zhu H, Shui P. The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology. Front Oncol 2020;10:570465. [PMID: 33575207 DOI: 10.3389/fonc.2020.570465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
231 Shah AD, Bouchard MJ, Shieh AC. Interstitial Fluid Flow Increases Hepatocellular Carcinoma Cell Invasion through CXCR4/CXCL12 and MEK/ERK Signaling. PLoS One 2015;10:e0142337. [PMID: 26560447 DOI: 10.1371/journal.pone.0142337] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
232 Yu X, Zhang J, Yang R, Li C. Identification of Long Noncoding RNA Biomarkers for Hepatocellular Carcinoma Using Single-Sample Networks. Biomed Res Int 2020;2020:8579651. [PMID: 33299877 DOI: 10.1155/2020/8579651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Li Y, Li Y, Chen Y, Xie Q, Dong N, Gao Y, Deng H, Lu C, Wang S. MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis. Cancer Cell Int 2017;17:102. [PMID: 29151817 DOI: 10.1186/s12935-017-0471-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
234 Yılmaz Susluer S, Kayabasi C, Ozmen Yelken B, Asik A, Celik D, Balci Okcanoglu T, Serin Senger S, Biray Avci C, Kose S, Gunduz C. Analysis of long non-coding RNA (lncRNA) expression in hepatitis B patients. Bosn J Basic Med Sci 2018;18:150-61. [PMID: 29669510 DOI: 10.17305/bjbms.2018.2800] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
235 Li N, Zhao L, Guo C, Liu C, Liu Y. Identification of a novel DNA repair-related prognostic signature predicting survival of patients with hepatocellular carcinoma. Cancer Manag Res 2019;11:7473-84. [PMID: 31496805 DOI: 10.2147/CMAR.S204864] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
236 Song T, Wang C, Guo C, Liu Q, Zheng X. Pentraxin 3 overexpression accelerated tumor metastasis and indicated poor prognosis in hepatocellular carcinoma via driving epithelial-mesenchymal transition. J Cancer 2018;9:2650-8. [PMID: 30087705 DOI: 10.7150/jca.25188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
237 Meng FL, Wang W, Jia WD. Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma. Med Oncol. 2014;31:177. [PMID: 25129312 DOI: 10.1007/s12032-014-0177-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
238 Finianos A, Matar CF, Taher A. Hepatocellular Carcinoma in β-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis. Int J Mol Sci 2018;19:E4070. [PMID: 30562917 DOI: 10.3390/ijms19124070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
239 Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology 2015;149:119-29. [PMID: 25836985 DOI: 10.1053/j.gastro.2015.03.044] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
240 Song WH, Feng XJ, Gong SJ, Chen JM, Wang SM, Xing DJ, Zhu MH, Zhang SH, Xu AM. microRNA-622 acts as a tumor suppressor in hepatocellular carcinoma. Cancer Biol Ther 2015;16:1754-63. [PMID: 26467022 DOI: 10.1080/15384047.2015.1095402] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
241 Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, Iloeje UH, You SL, Brenner D, Chen CJ; REVEAL–HBV Study Group. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol 2013;11:1636-45.e1-3. [PMID: 23669307 DOI: 10.1016/j.cgh.2013.04.043] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
242 Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Front Immunol 2020;11:568759. [PMID: 33117354 DOI: 10.3389/fimmu.2020.568759] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
243 Ye ZH, Gao L, Wen DY, He Y, Pang YY, Chen G. Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas. Onco Targets Ther 2017;10:1711-23. [PMID: 28356759 DOI: 10.2147/OTT.S132120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
244 Maeda S, Wada H, Naito Y, Nagano H, Simmons S, Kagawa Y, Naito A, Kikuta J, Ishii T, Tomimaru Y, Hama N, Kawamoto K, Kobayashi S, Eguchi H, Umeshita K, Ishii H, Doki Y, Mori M, Ishii M. Interferon-α acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line. J Biol Chem 2014;289:23786-95. [PMID: 25012666 DOI: 10.1074/jbc.M114.551879] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 3.9] [Reference Citation Analysis]
245 Sadeeshkumar V, Duraikannu A, Ravichandran S, Kodisundaram P, Fredrick WS, Gobalakrishnan R. Modulatory efficacy of dieckol on xenobiotic-metabolizing enzymes, cell proliferation, apoptosis, invasion and angiogenesis during NDEA-induced rat hepatocarcinogenesis. Mol Cell Biochem 2017;433:195-204. [PMID: 28397013 DOI: 10.1007/s11010-017-3027-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
246 Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open Access Maced J Med Sci. 2015;3:732-736. [PMID: 27275318 DOI: 10.3889/oamjms.2015.111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 9.7] [Reference Citation Analysis]
247 De P, Dryer D, Otterstatter MC, Semenciw R. Canadian trends in liver cancer: a brief clinical and epidemiologic overview. Curr Oncol 2013;20:e40-3. [PMID: 23443230 DOI: 10.3747/co.20.1190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
248 Qin XY, Su T, Yu W, Kojima S. Lipid desaturation-associated endoplasmic reticulum stress regulates MYCN gene expression in hepatocellular carcinoma cells. Cell Death Dis 2020;11:66. [PMID: 31988297 DOI: 10.1038/s41419-020-2257-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
249 Wang C, Xie H, Lu D, Ling Q, Jin P, Li H, Zhuang R, Xu X, Zheng S. The MTHFR polymorphism affect the susceptibility of HCC and the prognosis of HCC liver transplantation. Clin Transl Oncol 2018;20:448-56. [PMID: 29185200 DOI: 10.1007/s12094-017-1729-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
250 Liu J, Pei Y, Zhang Y, Wu Y, Liu F, Gu S. Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features. Abdom Radiol (NY) 2021;46:3748-57. [PMID: 33386449 DOI: 10.1007/s00261-020-02891-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
251 Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014;8:177-185. [PMID: 24672660 DOI: 10.5009/gnl.2014.8.2.177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
252 Dastjerdi MN, Kavoosi F, Valiani A, Esfandiari E, Sanaei M, Sobhanian S, Hakemi MG, Mobarakian M. Inhibitory Effect of Genistein on PLC/PRF5 Hepatocellular Carcinoma Cell Line. Int J Prev Med 2015;6:54. [PMID: 26180625 DOI: 10.4103/2008-7802.158914] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
253 Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012;55:483-90. [PMID: 21953299 DOI: 10.1002/hep.24703] [Cited by in Crossref: 185] [Cited by in F6Publishing: 185] [Article Influence: 18.5] [Reference Citation Analysis]
254 Zhao ZB, Chen F, Bai XF. Long Noncoding RNA MALAT1 Regulates Hepatocellular Carcinoma Growth Under Hypoxia via Sponging MicroRNA-200a. Yonsei Med J 2019;60:727-34. [PMID: 31347327 DOI: 10.3349/ymj.2019.60.8.727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
255 Lo TF, Tsai WC, Chen ST. MicroRNA-21-3p, a berberine-induced miRNA, directly down-regulates human methionine adenosyltransferases 2A and 2B and inhibits hepatoma cell growth. PLoS One. 2013;8:e75628. [PMID: 24098708 DOI: 10.1371/journal.pone.0075628] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 8.6] [Reference Citation Analysis]
256 de Carvalho FM, de Almeida Pereira T, Gonçalves PL, Jarske RD, Pereira FE, Louro ID. Hepatocellular carcinoma and liver cirrhosis TP53 mutation analysis reflects a moderate dietary exposure to aflatoxins in Espírito Santo State, Brazil. Mol Biol Rep 2013;40:4883-7. [PMID: 23649769 DOI: 10.1007/s11033-013-2587-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
257 Fan G, Tu Y, Chen C, Sun H, Wan C, Cai X. DNA methylation biomarkers for hepatocellular carcinoma. Cancer Cell Int 2018;18:140. [PMID: 30245591 DOI: 10.1186/s12935-018-0629-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
258 Zhang H, Liu H, Bi H. MicroRNA-345 inhibits hepatocellular carcinoma metastasis by inhibiting YAP1. Oncol Rep 2017;38:843-9. [PMID: 28677785 DOI: 10.3892/or.2017.5772] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
259 Masior Ł, Grąt M, Grąt K, Krasnodębski M, Wronka KM, Stypułkowski J, Patkowski W, Frączek M, Krawczyk M, Zieniewicz K. Importance of Intraoperative Transfusions of Packed Red Blood Cells and Fresh Frozen Plasma in Liver Transplantation for Hepatocellular Cancer. Ann Transplant 2020;25:e923665. [PMID: 33079923 DOI: 10.12659/AOT.923665] [Reference Citation Analysis]
260 Teng CF, Yu CH, Chang HY, Hsieh WC, Wu TH, Lin JH, Wu HC, Jeng LB, Su IJ. Chemopreventive Effect of Phytosomal Curcumin on Hepatitis B Virus-Related Hepatocellular Carcinoma in A Transgenic Mouse Model. Sci Rep 2019;9:10338. [PMID: 31316146 DOI: 10.1038/s41598-019-46891-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
261 Cidon EU. Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol 2017; 9(18): 797-807 [PMID: 28706578 DOI: 10.4254/wjh.v9.i18.797] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
262 Parsons HM, Chu Q, Karlitz JJ, Stevens JL, Harlan LC. Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States. Liver Cancer 2017;6:216-26. [PMID: 29234628 DOI: 10.1159/000473862] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
263 Wang F, Yang JL, Yu KK, Xu M, Xu YZ, Chen L, Lu YM, Fang HS, Wang XY, Hu ZQ, Li FF, Kan L, Luo J, Wang SY. Activation of the NF-κB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma. Mol Cancer 2015;14:10. [PMID: 25622857 DOI: 10.1186/s12943-014-0274-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 8.2] [Reference Citation Analysis]
264 Erejuwa OO, Sulaiman SA, Wahab MS. Effects of honey and its mechanisms of action on the development and progression of cancer. Molecules. 2014;19:2497-2522. [PMID: 24566317 DOI: 10.3390/molecules19022497] [Cited by in Crossref: 94] [Cited by in F6Publishing: 70] [Article Influence: 13.4] [Reference Citation Analysis]
265 Liu Q, Yang P, Tu K, Zhang H, Zheng X, Yao Y, Liu Q. TPX2 knockdown suppressed hepatocellular carcinoma cell invasion via inactivating AKT signaling and inhibiting MMP2 and MMP9 expression. Chin J Cancer Res 2014;26:410-7. [PMID: 25232213 DOI: 10.3978/j.issn.1000-9604.2014.08.01] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
266 Maponga TG, Glashoff RH, Vermeulen H, Robertson B, Burmeister S, Bernon M, Omoshoro-Jones J, Ruff P, Neugut AI, Jacobson JS, Preiser W, Andersson MI. Hepatitis B virus-associated hepatocellular carcinoma in South Africa in the era of HIV. BMC Gastroenterol. 2020;20:226. [PMID: 32660431 DOI: 10.1186/s12876-020-01372-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
267 Kim YH, Jeong DC, Pak K, Han ME, Kim JY, Liangwen L, Kim HJ, Kim TW, Kim TH, Hyun DW, Oh SO. SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma. Oncotarget 2017;8:68381-92. [PMID: 28978124 DOI: 10.18632/oncotarget.20266] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]
268 Fako V, Wang XW. The status of transarterial chemoembolization treatment in the era of precision oncology. Hepat Oncol 2017;4:55-63. [PMID: 28989699 DOI: 10.2217/hep-2017-0009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
269 Zhu SL, Zhong JH, Ke Y, Ma L, You XM, Li LQ. Efficacy of hepatic resection vs transarterial chemoembolization for solitary huge hepatocellular carcinoma. World J Gastroenterol 2015; 21(32): 9630-9637 [PMID: 26327771 DOI: 10.3748/wjg.v21.i32.9630] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
270 Jeng KS, Sheen IS, Jeng WJ, Yu MC, Tsai HH, Chang FY, Su JC. Blockade of the sonic hedgehog pathway effectively inhibits the growth of hepatoma in mice: An in vivo study. Oncol Lett. 2012;4:1158-1162. [PMID: 23205113 DOI: 10.3892/ol.2012.935] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
271 Shah RM, Sheikh S, Shah J, Vivian E, Mejia A, Shahin I, Mantry PS. Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center. J Gastrointest Oncol 2021;12:1718-31. [PMID: 34532122 DOI: 10.21037/jgo-20-435] [Reference Citation Analysis]
272 Wu HC, Yang HI, Wang Q, Chen CJ, Santella RM. Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population. Carcinogenesis 2017;38:1021-8. [PMID: 28981677 DOI: 10.1093/carcin/bgx078] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
273 Chow EY, Zhang J, Qin H, Chan TF. Characterization of Hepatocellular Carcinoma Cell Lines Using a Fractionation-Then-Sequencing Approach Reveals Nuclear-Enriched HCC-Associated lncRNAs. Front Genet 2019;10:1081. [PMID: 31781161 DOI: 10.3389/fgene.2019.01081] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
274 Zhang Z. Association between KIF1B rs17401966 polymorphism and hepatocellular carcinoma risk: a meta-analysis involving 17,210 subjects. Tumour Biol. 2014;35:9405-9410. [PMID: 24952890 DOI: 10.1007/s13277-014-2192-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
275 Su T, Qin XY, Dohmae N, Wei F, Furutani Y, Kojima S, Yu W. Inhibition of Ganglioside Synthesis Suppressed Liver Cancer Cell Proliferation through Targeting Kinetochore Metaphase Signaling. Metabolites 2021;11:167. [PMID: 33803928 DOI: 10.3390/metabo11030167] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
276 de Carvalho LR, Borrego A, Jensen JR, Cabrera WHK, Santos AM, Ribeiro OG, Starobinas N, De Franco M, Dragani TA, Manenti G, Ibañez OCM. Genetic Predisposition to Hepatocarcinogenesis in Inbred and Outbred Mouse Lines Selected for High or Low Inflammatory Response. J Immunol Res 2019;2019:5298792. [PMID: 31049358 DOI: 10.1155/2019/5298792] [Reference Citation Analysis]
277 Tavakoli H, Robinson A, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, Wong RJ. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. Dig Dis Sci. 2017;62:2174-2181. [PMID: 28474143 DOI: 10.1007/s10620-017-4595-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
278 Wang W, Iyer NG, Tay HT, Wu Y, Lim TK, Zheng L, Song IC, Kwoh CK, Huynh H, Tan PO, Chow PK. Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma. BMC Cancer 2015;15:828. [PMID: 26520397 DOI: 10.1186/s12885-015-1814-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
279 Qin XY, Suzuki H, Honda M, Okada H, Kaneko S, Inoue I, Ebisui E, Hashimoto K, Carninci P, Kanki K, Tatsukawa H, Ishibashi N, Masaki T, Matsuura T, Kagechika H, Toriguchi K, Hatano E, Shirakami Y, Shiota G, Shimizu M, Moriwaki H, Kojima S. Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid. Proc Natl Acad Sci U S A 2018;115:4969-74. [PMID: 29686061 DOI: 10.1073/pnas.1802279115] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 13.7] [Reference Citation Analysis]
280 Shiozawa K, Watanabe M, Ikehara T, Matsukiyo Y, Kogame M, Kishimoto Y, Okubo Y, Makino H, Tsukamoto N, Igarashi Y, Sumino Y. Comparison of percutaneous radiofrequency ablation and CyberKnife® for initial solitary hepatocellular carcinoma: A pilot study. World J Gastroenterol 2015; 21(48): 13490-13499 [PMID: 26730160 DOI: 10.3748/wjg.v21.i48.13490] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
281 Balasus D, Way M, Fusilli C, Mazza T, Morgan MY, Cervello M, Giannitrapani L, Soresi M, Agliastro R, Vinciguerra M, Montalto G. The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population. Oncotarget 2016;7:86791-802. [PMID: 27888630 DOI: 10.18632/oncotarget.13558] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
282 Li C, Wu L, Liu P, Li K, Zhang Z, He Y, Liu Q, Jiang P, Yang Z, Liu Z, Yuan Y, Chang L. The C/D box small nucleolar RNA SNORD52 regulated by Upf1 facilitates Hepatocarcinogenesis by stabilizing CDK1. Theranostics 2020;10:9348-63. [PMID: 32802196 DOI: 10.7150/thno.47677] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
283 Qiu L, Wang T, Xu X, Wu Y, Tang Q, Chen K. Long Non-Coding RNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Regulation, Functions, and Underlying Mechanisms. Int J Mol Sci 2017;18:E2505. [PMID: 29168767 DOI: 10.3390/ijms18122505] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
284 McKillop IH, Schrum LW, Thompson KJ. Role of alcohol in the development and progression of hepatocellular carcinoma. Hepat Oncol 2016;3:29-43. [PMID: 30191025 DOI: 10.2217/hep.15.40] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
285 Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:542-552. [PMID: 23689081 DOI: 10.1038/nrgastro.2013.87] [Cited by in Crossref: 367] [Cited by in F6Publishing: 361] [Article Influence: 45.9] [Reference Citation Analysis]
286 Tonon F, Farra R, Zennaro C, Pozzato G, Truong N, Parisi S, Rizzolio F, Grassi M, Scaggiante B, Zanconati F, Bonazza D, Grassi G, Dapas B. Xenograft Zebrafish Models for the Development of Novel Anti-Hepatocellular Carcinoma Molecules. Pharmaceuticals (Basel) 2021;14:803. [PMID: 34451900 DOI: 10.3390/ph14080803] [Reference Citation Analysis]
287 He M, Zhang W, Dong Y, Wang L, Fang T, Tang W, Lv B, Chen G, Yang B, Huang P, Xia J. Pro-inflammation NF-κB signaling triggers a positive feedback via enhancing cholesterol accumulation in liver cancer cells. J Exp Clin Cancer Res 2017;36:15. [PMID: 28100270 DOI: 10.1186/s13046-017-0490-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
288 Feng X, Song P, Bie P, Jiang P, Ma K, Li X, Wang S, Wang Z, Tang W, Zheng S. Des-γ-Carboxyprothrombin Plasma Level in Diagnosis of Hepatocellular Carcinoma in a Chinese Population Undergoing Surgery. Med Sci Monit 2016;22:1663-72. [PMID: 27187589 DOI: 10.12659/msm.895483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
289 Morine Y, Utsunomiya T, Saito Y, Yamada S, Imura S, Ikemoto T, Kitagawa A, Kobayashi Y, Takao S, Kosai K, Mimori K, Tanaka Y, Shimada M. Reduction of T-Box 15 gene expression in tumor tissue is a prognostic biomarker for patients with hepatocellular carcinoma. Oncotarget 2020;11:4803-12. [PMID: 33447348 DOI: 10.18632/oncotarget.27852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
290 Li A, Shuai X, Jia Z, Li H, Liang X, Su D, Guo W. Ganoderma lucidum polysaccharide extract inhibits hepatocellular carcinoma growth by downregulating regulatory T cells accumulation and function by inducing microRNA-125b. J Transl Med. 2015;13:100. [PMID: 25889022 DOI: 10.1186/s12967-015-0465-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
291 Li J, Dai X, Zhang H, Zhang W, Sun S, Gao T, Kou Z, Yu H, Guo Y, Du L, Jiang S, Zhang J, Zhou Y. Up-regulation of human cervical cancer proto-oncogene contributes to hepatitis B virus-induced malignant transformation of hepatocyte by down-regulating E-cadherin. Oncotarget 2015;6:29196-208. [PMID: 26470691 DOI: 10.18632/oncotarget.5039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
292 Liu M, Jiang L, Guan XY. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell. 2014;5:673-691. [PMID: 24916440 DOI: 10.1007/s13238- 014-0065-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
293 Xiao B, Liu C, Liu BT, Zhang X, Liu RR, Zhang XW. TTF1-NPs Induce ERS-Mediated Apoptosis and Inhibit Human Hepatoma Cell Growth In Vitro and In Vivo. Oncol Res. 2016;23:311-320. [PMID: 27131317 DOI: 10.3727/096504016X14567549091341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
294 Okazaki I, Noro T, Tsutsui N, Yamanouchi E, Kuroda H, Nakano M, Yokomori H, Inagaki Y. Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs). Cancers (Basel). 2014;6:1220-1255. [PMID: 24978432 DOI: 10.3390/cancers6031220] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
295 Zhang W, Zhou L, Yin P, Wang J, Lu X, Wang X, Chen J, Lin X, Xu G. A weighted relative difference accumulation algorithm for dynamic metabolomics data: long-term elevated bile acids are risk factors for hepatocellular carcinoma. Sci Rep 2015;5:8984. [PMID: 25757957 DOI: 10.1038/srep08984] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
296 Gong SJ, Feng XJ, Song WH, Chen JM, Wang SM, Xing DJ, Zhu MH, Zhang SH, Xu AM. Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma. Cancer Biol Ther 2016;17:151-62. [PMID: 26618405 DOI: 10.1080/15384047.2015.1121345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
297 Jiang YQ, Wang ZX, Deng YN, Yang Y, Wang GY, Chen GH. Efficacy of Hepatic Resection vs. Radiofrequency Ablation for Patients With Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study With Stratification by Age and Tumor Size. Front Oncol. 2019;9:113. [PMID: 30863723 DOI: 10.3389/fonc.2019.00113] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
298 Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Kaunas) 2019;55:E526. [PMID: 31450841 DOI: 10.3390/medicina55090526] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
299 Ding W, Tan H, Zhao C, Li X, Li Z, Jiang C, Zhang Y, Wang L. MiR-145 suppresses cell proliferation and motility by inhibiting ROCK1 in hepatocellular carcinoma. Tumour Biol. 2016;37:6255-6260. [PMID: 26615424 DOI: 10.1007/s13277-015-4462-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 6.5] [Reference Citation Analysis]
300 Lu DH, Lv WW, Li WX, Gao YD. High PKM2 expression is independently correlated with decreased overall survival in hepatocellular carcinoma. Oncol Lett 2018;16:3603-10. [PMID: 30127967 DOI: 10.3892/ol.2018.9100] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
301 Schwarze V, Marschner C, Völckers W, Grosu S, Negrão de Figueiredo G, Rübenthaler J, Clevert DA. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. J Int Med Res 2020;48:300060520930151. [PMID: 32529869 DOI: 10.1177/0300060520930151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
302 Huang ZJ, Zhu JJ, Yang XY, Biskup E. NEDD4 promotes cell growth and migration via PTEN/PI3K/AKT signaling in hepatocellular carcinoma. Oncol Lett 2017;14:2649-56. [PMID: 28928809 DOI: 10.3892/ol.2017.6532] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
303 Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L, Yan S, Wu L, Geng L, Ke Q, Gao F, Tu Z, Wang W, Zhang M, Shen Y, Xie H, Jiang W, Wang H, Zheng S. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut. 2016;65:1035-1041. [PMID: 25804634 DOI: 10.1136/gutjnl-2014-308513] [Cited by in Crossref: 83] [Cited by in F6Publishing: 89] [Article Influence: 13.8] [Reference Citation Analysis]
304 Robbins JR, Schmid RK, Hammad AY, Gamblin TC, Erickson BA. Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival. Cancer Med 2019;8:928-38. [PMID: 30701703 DOI: 10.1002/cam4.1948] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
305 Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Yip CS, Lu Z. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget 2016;7:6639-48. [PMID: 26735891 DOI: 10.18632/oncotarget.6781] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
306 Braunwarth E, Stättner S, Fodor M, Cardini B, Resch T, Oberhuber R, Putzer D, Bale R, Maglione M, Margreiter C, Schneeberger S, Öfner D, Primavesi F. Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. Eur Surg 2018;50:100-12. [PMID: 29875798 DOI: 10.1007/s10353-018-0537-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
307 Bort A, Spínola E, Rodríguez-Henche N, Díaz-Laviada I. Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation. Oncotarget 2017;8:87684-98. [PMID: 29152112 DOI: 10.18632/oncotarget.21196] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
308 White JA, Redden DT, Bryant MK, Dorn D, Saddekni S, Abdel Aal AK, Zarzour J, Bolus D, Smith JK, Gray S, Eckhoff DE, DuBay DA. Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. HPB (Oxford) 2014;16:1095-101. [PMID: 25158123 DOI: 10.1111/hpb.12313] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
309 Zhao QJ, Zhang J, Xu L, Liu FF. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. World J Gastroenterol 2018; 24(30): 3426-3439 [PMID: 30122881 DOI: 10.3748/wjg.v24.i30.3426] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 38] [Article Influence: 12.7] [Reference Citation Analysis]
310 Mihor A, Tomsic S, Zagar T, Lokar K, Zadnik V. Socioeconomic inequalities in cancer incidence in Europe: a comprehensive review of population-based epidemiological studies. Radiol Oncol 2020;54:1-13. [PMID: 32074075 DOI: 10.2478/raon-2020-0008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
311 Xu XS, Qu K, Liu C, Zhang YL, Liu J, Song YZ, Zhang P, Liu SN, Chang HL. Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma. World J Gastroenterol 2012; 18(48): 7242-7250 [PMID: 23326129 DOI: 10.3748/wjg.v18.i48.7242] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
312 Li J, Li J, Bao Y, Pan K, Lin X, Liu X, Wang H, Xu Y, Luo X, Li H, Duan C. Low Frequency of Peripheral Lymphocyte in Chronic Hepatitis B Patients Predicts Poor Progression to Hepatocellular Carcinoma. J Clin Lab Anal 2016;30:208-15. [PMID: 25600684 DOI: 10.1002/jcla.21838] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
313 Chiu AP, Tschida BR, Sham TT, Lo LH, Moriarity BS, Li XX, Lo RC, Hinton DE, Rowlands DK, Chan CO, Mok DKW, Largaespada DA, Warner N, Keng VW. HBx-K130M/V131I Promotes Liver Cancer in Transgenic Mice via AKT/FOXO1 Signaling Pathway and Arachidonic Acid Metabolism. Mol Cancer Res. 2019;17:1582-1593. [PMID: 30975706 DOI: 10.1158/1541-7786.mcr-18-1127] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
314 Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Postoperative aspartate aminotransferase to platelet ratio index change predicts prognosis for hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e4160. [PMID: 27472685 DOI: 10.1097/MD.0000000000004160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
315 Brito AF, Abrantes AM, Tralhão JG, Botelho MF. Targeting Hepatocellular Carcinoma: What did we Discover so Far? Oncol Rev 2016;10:302. [PMID: 27994769 DOI: 10.4081/oncol.2016.302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
316 Kolly P, Dufour JF. Surveillance for Hepatocellular Carcinoma in Patients with NASH. Diagnostics (Basel). 2016;6. pii:E22. [PMID: 27338480 DOI: 10.3390/diagnostics6020022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
317 Mehra M, Chauhan R. Long Noncoding RNAs as a Key Player in Hepatocellular Carcinoma. Biomark Cancer 2017;9:1179299X17737301. [PMID: 29147078 DOI: 10.1177/1179299X17737301] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
318 Zhao NN, Wang C, Lai CC, Cheng SJ, Yan J, Hong ZX, Yu LX, Zhu ZY, Zhang PR, Wang ZH, Wang XL, Zhang SG, Yang PH. Downregulation of BRAF-activated non-protein coding RNA in patients with hepatitis B virus-associated hepatocellular carcinoma. Oncol Lett 2018;15:7794-8. [PMID: 29725471 DOI: 10.3892/ol.2018.8327] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
319 Dai H, Jia G, Wang H, Yang J, Jiang H, Chu M. Epidermal growth factor receptor transactivation is involved in the induction of human hepatoma SMMC7721 cell proliferation by insufficient radiofrequency ablation. Oncol Lett 2017;14:2463-7. [PMID: 28789459 DOI: 10.3892/ol.2017.6463] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
320 Liang KH, Yang PC, Yeh CT. Genotyping the GALNT14 gene by joint analysis of two linked single nucleotide polymorphisms using liver tissues for clinical and geographical comparisons. Oncol Lett 2014;8:2215-20. [PMID: 25295111 DOI: 10.3892/ol.2014.2507] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
321 Ni JY, Sun HL, Chen YT, Luo JH, Chen D, Jiang XY, Xu LF. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma. World J Gastroenterol 2014; 20(46): 17483-17490 [PMID: 25516662 DOI: 10.3748/wjg.v20.i46.17483] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
322 Ladenheim MR, Kim NG, Nguyen P, Le A, Stefanick ML, Garcia G, Nguyen MH. Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study. BMJ Open Gastroenterol 2016;3:e000107. [PMID: 27493763 DOI: 10.1136/bmjgast-2016-000107] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
323 He M, Hou J, Wang L, Zheng M, Fang T, Wang X, Xia J. Actinidia chinensis Planch root extract inhibits cholesterol metabolism in hepatocellular carcinoma through upregulation of PCSK9. Oncotarget 2017;8:42136-48. [PMID: 28178673 DOI: 10.18632/oncotarget.15010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
324 Ni JY, Xu LF, Wang WD, Sun HL, Chen YT. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: A meta-analysis. World J Gastroenterol 2014; 20(45): 17206-17217 [PMID: 25493037 DOI: 10.3748/wjg.v20.i45.17206] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
325 Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol 2015; 7(12): 1708-1717 [PMID: 26140091 DOI: 10.4254/wjh.v7.i12.1708] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
326 Yang C, Yun Q, Sun H, Yang G, Liang T, Zhang C, Song J, Han J, Hou G. Non-invasive imaging of Toll-like receptor 5 expression using 131I-labeled mAb in the mice bearing H22 tumors. Oncol Lett 2014;7:1919-24. [PMID: 24932259 DOI: 10.3892/ol.2014.2025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
327 Teng CF, Wu HC, Su IJ, Jeng LB. Hepatitis B Virus Pre-S Mutants as Biomarkers and Targets for the Development and Recurrence of Hepatocellular Carcinoma. Viruses 2020;12:E945. [PMID: 32859114 DOI: 10.3390/v12090945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
328 Shastri A, Shastri SS. Cancer screening and prevention in low-resource settings. Nat Rev Cancer 2014;14:822-9. [PMID: 25355377 DOI: 10.1038/nrc3859] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
329 Kennedy K, Graham SM, Arora N, Shuhart MC, Kim HN. Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis. PLoS One 2018;13:e0204031. [PMID: 30252863 DOI: 10.1371/journal.pone.0204031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
330 Al-Dali AM, Weiher H, Schmidt-Wolf IGH. Utilizing ethacrynic acid and ciclopirox olamine in liver cancer. Oncol Lett 2018;16:6854-60. [PMID: 30405829 DOI: 10.3892/ol.2018.9472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
331 Chen JH, Wang YY, Lv WB, Gan Y, Chang W, Tian NN, Huang XH, Liu L, Yu XF, Chen SD. Effects of interactions between environmental factors and KIF1B genetic variants on the risk of hepatocellular carcinoma in a Chinese cohort. World J Gastroenterol 2016; 22(16): 4183-4190 [PMID: 27122668 DOI: 10.3748/wjg.v22.i16.4183] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
332 Orlacchio A, Chegai F, Del Giudice C, Massaccesi M, Costanzo E, Di Caprera E, Simonetti G. Radiofrequency thermoablation of HCC larger than 3 cm and less than 5 cm proximal to the gallbladder without gallbladder isolation: a single center experience. Biomed Res Int 2014;2014:896527. [PMID: 25247192 DOI: 10.1155/2014/896527] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
333 Hesketh RL, Zhu AX, Oklu R. Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma? Diagn Interv Radiol 2015;21:78-84. [PMID: 25430530 DOI: 10.5152/dir.2014.14237] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
334 Wang X, Liao Z, Bai Z, He Y, Duan J, Wei L. MiR-93-5p Promotes Cell Proliferation through Down-Regulating PPARGC1A in Hepatocellular Carcinoma Cells by Bioinformatics Analysis and Experimental Verification. Genes (Basel). 2018;9:E51. [PMID: 29361788 DOI: 10.3390/genes9010051] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
335 Schiefelbein E, Zekri AR, Newton DW, Soliman GA, Banerjee M, Hung ChW, Seifeldin IA, Lo AC, Soliman AS. Hepatitis C virus and other risk factors in hepatocellular carcinoma. Acta Virol 2012;56:235-40. [PMID: 23043603 DOI: 10.4149/av_2012_03_235] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
336 Chen M, Luo F, Yu J, Xiang G, Jiang D, Pu X. Common functional polymorphism within miR-146a and miR-196a-2 as susceptibility loci for hepatocellular carcinoma: An updated meta-analysis. Meta Gene 2016;7:40-7. [PMID: 26862480 DOI: 10.1016/j.mgene.2015.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
337 Xue S, Lu F, Sun C, Zhao J, Zhen H, Li X. LncRNA ZEB1-AS1 regulates hepatocellular carcinoma progression by targeting miR-23c. World J Surg Oncol 2021;19:121. [PMID: 33865414 DOI: 10.1186/s12957-021-02176-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
338 Ali F, Rahul, Jyoti S, Fatima A, Khanam S, Naz F, Siddique YH. Protective Role of Curcumin against N-Nitrosodiethylamine (NDEA)-Induced Toxicity in Rats. Sci Pharm 2016;84:361-77. [PMID: 27222610 DOI: 10.3797/scipharm.1506-06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
339 Qin A, Zhu J, Liu X, Zeng D, Gu M, Lv C. MicroRNA-1271 inhibits cellular proliferation of hepatocellular carcinoma. Oncol Lett 2017;14:6783-8. [PMID: 29181102 DOI: 10.3892/ol.2017.7052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
340 Zhong DN, Ning QY, Wu JZ, Zang N, Wu JL, Hu DF, Luo SY, Huang AC, Li LL, Li GJ. Comparative proteomic profiles indicating genetic factors may involve in hepatocellular carcinoma familial aggregation. Cancer Sci. 2012;103:1833-1838. [PMID: 22726459 DOI: 10.1111/j.1349-7006.2012.02368.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
341 Okoronkwo N, Wang Y, Pitchumoni C, Koneru B, Pyrsopoulos N. Improved Outcomes Following Hepatocellular Carcinoma (HCC) Diagnosis in Patients Screened for HCC in a Large Academic Liver Center versus Patients Identified in the Community. J Clin Transl Hepatol 2017;5:31-4. [PMID: 28507924 DOI: 10.14218/JCTH.2016.00051] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
342 Liu M, Jiang L, Guan XY. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell 2014;5:673-91. [PMID: 24916440 DOI: 10.1007/s13238-014-0065-9] [Cited by in Crossref: 80] [Cited by in F6Publishing: 89] [Article Influence: 11.4] [Reference Citation Analysis]
343 Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7:12870. [PMID: 28993684 DOI: 10.1038/s41598-017-12834-1] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 14.8] [Reference Citation Analysis]
344 Kamaraju S, Drope J, Sankaranarayanan R, Shastri S. Cancer Prevention in Low-Resource Countries: An Overview of the Opportunity. Am Soc Clin Oncol Educ Book 2020;40:1-12. [PMID: 32239989 DOI: 10.1200/EDBK_280625] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
345 Zamboni CG, Kozielski KL, Vaughan HJ, Nakata MM, Kim J, Higgins LJ, Pomper MG, Green JJ. Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. J Control Release 2017;263:18-28. [PMID: 28351668 DOI: 10.1016/j.jconrel.2017.03.384] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]